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CHAPTER I 
 
INTRODUCTION 
 
Protein kinase signal transduction 
Encoded among an estimated 20,000-25,000 protein-coded genes in humans (Reviewed 
in (Stein, 2004)) is an important group of proteins that comprise the protein kinase superfamily.  
Protein kinases catalyze the transfer ATP γ-phosphate onto hydroxyl groups of tyrosine, serine, or 
threonine amino acid residues of substrate proteins in a process called phosphorylation.  While 
protein phosphorylation and protein kinases were originally described in the mid 1950ʼs by 
Fischer & Krebs	  (Fischer, et al., 1955), and Sutherland & Wosilait	  (Sutherland, et al., 1955), the 
significance of protein phosphorylation as a regulatory mechanism wasnʼt realized until 14 years 
later	   (Linn, et al., 1969).  Currently there are 518 known protein kinases accounting for 
approximately 2% of genes in humans (Manning, et al., 2002).  Based on amino acid alignment, 
the protein kinase domain contains 11 highly conserved sub-domains consisting of 250-300 
amino acids divided into an N-terminal ATP binding lobe and C-terminal peptide binding and 
phosphotransfer lobe (Figure 1.1) (Hanks, et al., 1988; Hanks, 2003).  The conservation of 
particular residues and motifs across most protein kinases was hypothesized, and later 
demonstrated, to be critical for enzymatic activity (Hanks, et al., 1988).  Specifically, subdomain II 
contains a lysine that is important for binding and orienting the ATP molecule whereas aspartic 
acid and asparagine residues in the HRDLKxxN motif of subdomain VIb, combined with the 
aspartic acid in the DFG motif of subdomain VII, are important for phosphotransfer	  (Hanks, et al., 
1988).  Since protein phosphorylation is a reversible post-translational modification, it is a 
dynamic mechanism that can regulate protein function and gene expression by way of protein-
protein   interactions,  localization,   and   enzymatic  activity.     Hence,   many   cancer  therapies	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Figure 1.1: Conserved subdomains and key amino acid residues within the protein kinase 
domain The protein kinase domain consist of 11 subdomains highly conserved in all protein 
kinases.  Within these subdomains lie key amino acid residues, usually invariant, critical for 
enzymatic function.  In particular, the lysine residue in subdomain II is important for ATP binding 
and the aspartic acid residues in subdomains VIb and VII are involved in phosphotransfer of ATP 
γ-phosphate.  Letters represent amino acids as follows: Glycine (G), Lysine (K), Glutamic acid 
(E), Aspartic acid (D), Alanine (A), Proline (P), Arginine (R), and any amino acid (x). Figure from	  
(Hanks, 2003). 	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 utilize selective kinase inhibitors to inhibit pathways in which mutations have resulted in aberrant 
or dysregulated kinase signaling.  
 
TNF signaling 
The pro-inflammatory cytokine TNF was originally described in 1975 by Carswell and 
characterized as a necrosis-inducing agent in mouse and human sarcomas (Carswell, et al., 
1975; Haranaka, et al., 1981; Haranaka, et al., 1984).  The major source of TNF is produced by 
macrophage and monocytes in response to infection.  TNF transcripts are translated as 
membrane anchored precursors that are cleaved into soluble peptides by the activity of TNF 
converting enzyme (TACE)	  (Black, et al., 1997).  While TNF can bind either of two TNF receptors 
(TNFR1 & TNFR2), much attention has been given to TNFR1 signaling due to its role in cell death 
pathways via its conserved death domain (DD).  Thus, TNFR1 is the prototypic member among 
several death receptors in the larger TNFR superfamily.  Like many cell surface receptors, 
signaling through TNFR1 is initiated at the cell surface, which activates signaling pathways that 
control cellular processes including growth arrest, cell survival, and apoptosis (Edelblum, et al., 
2008; Kaiser, et al., 1999).  Since TNFR1 lacks intrinsic kinase activity, signal transduction is 
mediated by the recruitment of DD-containing adaptor proteins to the TNFR1 DD (Figure 1.2).  
Ligation of TNF to TNFR1 recruits the DD-containing adaptor molecule TNF receptor-associated 
death domain (TRADD).  TRADD recruits other adaptor proteins including the protein kinase 
receptor-interacting protein (RIP), TNF-R-associated factor 2 (TRAF2), and Fas-associated death 
domain (FADD).  While FADD couples to the apoptotic pathway through the recruitment and 
activation of caspase-8, TRAF2 binds cellular inhibitor of apoptosis protein-1 (cIAP-1), inhibiting 
caspase activity	  (Uren, et al., 1996).  In addition, TRAF2 and RIP activate IκB kinase (IKK), which 
phosphorylates IκB promoting its degradation and subsequent release of nuclear factor-κB (NF-
κB).  Upon NF-κB release and nuclear translocation, cIAP is upregulated, contributing to cell 
survival responses (Devin, et al., 2000).  Furthermore, the cytoplasmic tail of TNFR1 contains a 
neutral sphingomyelinase (N-SMase) domain that  stimulates N-SMase activity,  which hydrolyzes 
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Figure 1.2: Pro- and anti-apoptotic signaling through TNFR1 Binding of TNF to homotrimeric 
TNFR1 triggers assembly of the death domain containing proteins TRADD and FADD to the 
TNFR1 death domain.  FADD recruits pro-caspase 8 that undergoes auto-cleavage and activates 
effector caspases promoting apoptosis.  TRAF2 also binds FADD and activates pro-apoptotic 
signaling cascades through p38 and JNK.  In addition, TRAF2 promotes activation of anti-
apoptotic targets ERK and AKT and RIP-mediated activation of the NF-κB pathway. 	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the membrane lipid sphingomyelin to generate ceramide.  Ceramide promotes activation of 
kinase suppressor of Ras 1 (KSR1) and stimulates KSR1 kinase activity towards Raf-1 (Zhang, et 
al., 1997).  Activation of Raf-1 leads to extracellular-signal-regulated kinase (ERK) activation, 
which promotes cell survival by phosphorylating the mitochondrial membrane protein Bcl-2 on 
Ser87, blocking cytochrome c release (Deng, et al., 2004; Tamura, et al., 2004).  Previous data 
from our lab indicate that the activities of both ERK and NF-κB pathways function synergistically 
to promote cell survival in colon epithelial cells following TNF treatment (Yan, et al., 2001).  Given 
the pleiotropic nature of TNF in a variety of cell types, understanding the mechanisms that 
contribute to the biological consequences of TNFR1 activation has implications for inflammatory 
diseases in which TNF is upregulated.   
 
The ERK pathway 
Canonical activation of the ERK/mitogen-activated protein kinase (MAPK) cascade 
occurs via a three-tiered kinase module that is initiated by many G protein-coupled receptors 
(GPCRs) or receptor tyrosine kinases (RTKs) (Figure 1.3A). Downstream of GPCRs and RTK 
activation, a membrane-anchored small GTPase known as Ras recruits the MAPK kinase kinase 
Raf-1 to the plasma membrane.  Raf-1 translocation to the plasma membrane occurs following 
release of 14-3-3 proteins upon dephosphorylation of Ser259 by protein phosphatase 2A (PP2A) 
(Abraham, et al., 2000).  While the complete mechanism of Raf-1 activation is not entirely 
understood, phosphorylation by KSR1 on Thr269 and phosphorylation of Ser338 by p21-activated 
protein kinase (Pak) are reported to stimulate Raf-1 kinase activity (King, et al., 1998; Xing, et al., 
2001).  Activated Raf-1 propagates signal transduction by phosphorylating and activating the dual 
specificity MAPK/ERK kinase (MEK) by direct phosphorylation of Ser217 and Ser221 in the MEK 
activation loop	  (Yan, et al., 1994).  Activated MEK phosphorylates ERK1/2 on both threonine and 
tyrosine residues resulting in ERK activation (reviewed in	   (Roux, et al., 2004)).  Following 
activation, ERK translocates into the nucleus where it phosphorylates a number of transcription 
6 
factors to regulate gene expression.  While the ERK pathway has been extensively studied for the 
past 15 years, new data continues to emerge about the how this pathway is regulated.  For 
instance, in TNFR1 signaling, Raf-1 activation was shown to occur in a Ras-independent manner 
(Edelblum, et al., 2008).  In addition, recent evidence suggests that Raf-1 activation is enhanced 
via a dimerization-dependent mechanism with KSR1 (Rajakulendran, et al., 2009).  These data 
suggest that alternative mechanisms are involved in pathway activation that is likely cell-type and 
context-dependent. 
 
Kinase suppressor of Ras 1 
 
Identification 
Oncogenic mutations that confer constitutive activity in any of three Ras genes (H-Ras, 
K-Ras, or N-Ras) are found in many human adenocarcinomas (90% of pancreatic and 50% of 
colon cancers) (Bos, 1989).  Therefore, much effort has been made to identify molecules and 
understand the biochemical processes that regulate the Ras pathway.  To elucidate the 
mechanism by which the Ras effector protein Raf-1 becomes activated, three independent groups 
carried out forward genetic screens using chemical mutagenesis in Drosophila melanogaster and 
Caenorhabditis elegans to identify modifiers of the Ras pathway.  In Drosophila, ectopic 
expression of a Ras1V12 constitutively activated Ras allele in the developing eye results in a 
readily observable rough eye phenotype.  Therefore, mutant alleles that disrupt the constitutive 
Ras1V12 signaling would allow for normal eye development.  One particular mutant that was able 
to suppress the activated Ras1V12 was given the name kinase suppressor of Ras 1 because of its 
putative C-terminal kinase domain (Figure 1.3Bii) (Kornfeld, et al., 1995; Sundaram, et al., 1995; 
Therrien, et al., 1995).  Likewise, the multi-vulva phenotype induced by the constitutively active 
let-60 ras gene in C. elegans was suppressed by mutations in ksr-1 (Kornfeld, et al., 1995; 
Sundaram, et al., 1995).  To determine where KSR functioned in the Ras pathway, Therrien and 
colleagues crossed a KSR loss-of-function allele with an ectopically expressed constitutively 
7 
 
 
 
 
Figure 1.3:  Kinase suppressor of Ras 1 (KSR1) identified as a modifier of the Ras 
signaling pathway  A) Canonical activation of the Ras-Raf-MEK-ERK signaling pathway 
downstream of receptor tyrosine kinases (RTKs).  Activation of RTKs promotes activation of Ras, 
which binds and promotes Raf activation.  Activated Raf phosphorylates and activates MEK, 
which then phosphorylates and activates ERK.  Bi) Topography of a wild-type Drosophila eye Bii) 
Drosophila rough eye phenotype resulting from ectopic expression of a constitutively active 
RasV12.  Biii) Suppression of RasV12 activity as a result of a mutant that mapped to the ksr-1 locus.  
Biv) Rough eye phenotype resulting from ectopic expression of constitutively active raf tor4021.  Bv) 
Mutant ksr-1 is unable to suppress activated raf tor4021 phenotype.  
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active Raf-1 mutant that also produces a rough eye phenotype in Drosophila.  This genetic 
epistasis analysis placed KSR1 directly upstream or parallel to Raf-1 since the KSR1 loss-of-
function allele was unable to suppress the active Raf-1 phenotype (Figure 1.3Bv)	  (Therrien, et al., 
1995).  In the years following the initial discovery of KSR1, a brain-specific isoform (B-KSR1) has 
also been described (Müller, et al., 2000) as has a second KSR gene, named KSR2, which is 
found in C. elegans and mammals to have both unique and redundant functions with KSR1 
(Dougherty, et al., 2009; Ohmachi, et al., 2002). 
 
Structure of KSR1 
Amino acid alignments comparing KSR1 across multiple species revealed that KSR1 
contained five conserved areas (CA1-CA5) and is related to the Raf family of tyrosine kinase like 
(TKL) protein kinases (Figure 1.4) (Therrien, et al., 1995).  The CA1 domain is unique to KSR1 
proteins and in the original screen, a weak loss-of-function allele mapped to CA1, implicating a 
functional role for this domain in Ras signaling.  More recently it was reported that the CA1 
domain was involved in binding Raf proteins (McKay, et al., 2009).  This interaction with Raf is 
dependent on the ability of MEK to bind KSR1 since mutation of Cys809 in the KSR1 kinase 
domain, a position essential for MEK binding, abolished KSR1-Raf dimers (McKay, et al., 2009).  
This raises the possibility that an intramolecular interaction may exist between KSR1 CA1 and 
kinase domain and contribute to KSR1 structure and/or function.   
The second and third conserved areas consist of a proline-rich (CA2) and cysteine rich 
(CA3) domains respectively.  The proline rich CA2 domain corresponds to a src homology 3 
(SH3) recognition site while the cysteine rich CA3 domain is highly similar to both the CR1 
domain of Raf (while lacking the Ras binding domain), and the lipid-binding domain of protein 
kinase C-ζ (PKCζ).  In fact, the KSR1 CA3 domain facilitates membrane translocation and is 
hypothesized to bind the second messenger lipid ceramide, though results are conflicting 
(Michaud, et al., 1997; van Blitterswijk, 1998; Zhou, et al., 2002).  
9 
The serine/threonine rich CA4 domain is similar the CR2 domain in Raf-1, and the CA5 
domain contains the eleven subdomains conserved in all protein kinases.  The kinase domain of 
KSR1 has received much attention due to its unique features and conflicting reports surrounding 
catalytic activity.  The first unique features are found in subdomains VIb and VIII that are 
indicative of serine/threonine (S/T) or tyrosine kinases.  Typically S/T kinases contain HRDLKxxN 
in subdomain Vlb while tyrosine kinases contain HRDLR/AxA/RN.  For KSR1, the Drosophila 
homolog possesses an arginine in VIb indicative of a tyrosine kinase, while mammalian KSR1 
contains a lysine corresponding to a S/T kinase.  Another interesting feature for all KSR1 genes is 
that subdomain VIII contains a WxxY motif instead of T/SxxY/F for S/T kinases or PxxW found in 
tyrosine kinases.  Even still, the most divergent feature occurs in subdomain II of the mammalian 
KSR1 kinase domain.  Typically, an invariant lysine residue in subdomain II is critical for binding 
and orienting the ATP molecule and necessary for catalytic function (Hanks, et al., 1995).  While 
the Drosophila KSR1 homolog has this lysine present, mammalian KSR1 contains an arginine in 
this position.  Most protein kinases are rendered catalytically inactive when this lysine is 
substituted with arginine or methionine (Cotten, et al., 2003; Ebina, et al., 1987; Gibbs, et al., 
1991; Snyder, et al., 1985).  However, KSR1 is not the first protein kinase with variations in 
conserved residues, as the proteins with-no-lysine (WNK) and p53-related protein kinase (PRPK) 
contain variations in conserved sequences and possess enzymatic activity (Abe, et al., 2001; Xu, 
et al., 2000). 
 
Function and regulation of KSR1 
 The contribution of KSR1 in the ERK/MAPK signal transduction pathway has been 
demonstrated for a variety of cellular functions including Xenopus oocyte maturation, monocyte 
differentiation, NK cell-mediated lysis, and colon epithelial cell survival (Therrien, et al., 1996; 
Wang, et al., 2004, Giurisato, et al., 2009; Yan, et al., 2004).  The majority of studies conclude 
that the predominant function of KSR1 is to scaffold ERK/MAPK cascade components Raf-1, 
MEK,   and   ERK  	  (Denouel-Galy, et al., 1998; Therrien, et al., 1996).      As  mentioned   earlier,  
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Figure 1.4: Linear representation of KSR1 conserved domains and regulatory 
phosphorylation sites  KSR1 contains five conserved regions termed CA1-CA5.  CA1 is a 
domain unique to KSR1 and is involved in binding Raf proteins.  CA2 is a polyproline region 
corresponding to SH3 domain recognition.  CA3 is a cysteine rich motif involved in lipid binding 
and membrane translocation.  CA4 is a serine/threonine rich region and CA5 is a kinase domain.  
Phosphorylation sites demonstrated to be involved in regulation of KSR1 are depicted as serine 
(S) or threonine (T) with corresponding amino acid position.  Ser297 and Ser392 are C-TAK1 
phosphorylation sites that mediate 14-3-3 binding.  Phosphorylation of Ser274 and Ser392 
regulate the nucleocytoplasmic distribution of KSR1.  
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transient B-Raf binding occurs in the KSR1 CA1 domain (McKay, et al., 2009), whereas MEK is 
constitutively bound to KSR1 in the KSR1 kinase domain. KSR1 association with MEK is 
completely abolished when KSR1 Cys809 is mutated to tyrosine.   Since this cysteine residue is 
conserved even for Raf family members, it likely contributes to the structural integrity of the 
kinase domain itself.  Since substitution of KSR1 Arg589 in the ATP binding cleft of the kinase 
domain also reduces MEK binding, this position may also be critical for structural integrity (Yu, et 
al., 1998).   While KSR1 contains an FxFP consensus ERK binding site in CA4, the binding of 
KSR1 to ERK appears to be transient and only induced upon Ras activation (Cacace, et al., 1999; 
Müller, et al., 2000).  Thus, signal transduction through the ERK module is greatly enhanced by 
the ability of KSR1 to bind each component and bring them together to allow signal propagation 
from Ras to ERK. Just as KSR1 facilitates ERK pathway activation, it is also involved in 
attenuating ERK pathway activation.  Recently KSR1 was found to possess a DExD caspase 
cleavage site just upstream of the kinase domain.  This allows for rapid termination of survival 
cues stemming from ERK signaling once an apoptotic program is initiated (McKay, et al., 2007).   
While the role of KSR1 association with ERK cascade components has been well 
studied, other KSR1 interacting proteins including 14-3-3, Cdc25C-associated kinase 1 (C-TAK1), 
p50cdc37, heat shock protein 70 (Hsp70), γ subunit of G proteins, and Hsp90 also regulate KSR1 
function (Stewart, et al., 1999).  As with many proteins, phosphorylation regulates KSR1 function 
by modulating dynamics of the ERK signaling cascade.  KSR1 is constitutively phosphorylated on 
10 sites outside of the kinase domain by a number of protein kinases when overexpressed in 
HEK 293T cells	  (Volle, et al., 1999).  Of these sites, phosphorylation at Ser297 and Ser392 by C-
TAK1 mediates 14-3-3 binding and functions to sequester KSR1 in the cytosol (Müller, et al., 
2001).  Following stimulation, these sites are dephosphorylated by protein phosphatase 2A 
(PP2A) allowing for KSR1 membrane translocation and interactions with Raf (Ory, et al., 2003; 
Therrien, et al., 1996).  It is during this stimulus-induced association with Raf that MEK, and 
subsequently ERK, are activated.  Activated ERK phosphorylates KSR1, promoting dissociation 
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of KSR1 and B-Raf in a negative feedback loop releasing KSR1 from the plasma membrane 
(McKay, et al., 2009). In addition, phosphorylation of Thr274 and Ser392 on KSR1 regulates 
nuclear export and possibly regulates the duration of ERK activation in the absence of signaling 
at the level of Raf-1	  (Brennan, et al., 2002).   
While the kinase activity of KSR1 has been contentious, work from our lab and others 
support a catalytic role for KSR1 in the MAPK cascade.  Prior to KSR1 being discovered, data 
from Kolesnickʼs group show that TNF treatment stimulates a ceramide activated protein kinase 
(CAPK) to undergo autophosphorylation and direct phosphorylation of Raf-1 (Liu, et al., 1994; 
Yao, et al., 1995).  Following the cloning of KSR1, data from this same group demonstrate that 
KSR1 recapitulates previous results for CAPK, suggesting that these two proteins were one and 
the same (Xing, et al., 2000; Zhang, et al., 1997).  Though it is still unclear if autophosphorylation 
is a prerequisite for KSR1 activity towards Raf-1, phosphorylation of Raf-1 on Thr269 by KSR1 
increases Raf-1 activity towards MEK (Yan, et al., 2004; Zafrullah, et al., 2009; Zhang, et al., 
1997).  While our lab has recapitulated some of the findings surrounding the ability of KSR1 to 
phosphorylate Raf-1 in vitro (Yan, et al., 2004), others have suggested that the observed kinase 
activity is attributed to contaminating protein kinases complexed with KSR1 in these in vitro 
assays (Michaud, et al., 1997; Volle, et al., 1999).  Thus, the controversy surrounding KSR1 
catalytic activity has not been resolved since evidence for KSR1 enzymatic function has relied 
upon in vitro kinase assays utilizing immunoprecipitated KSR1 from mammalian cells.  Therefore, 
interpretation of previous data remains inconclusive and warrants new approaches to determine if 
KSR1 functions as a protein kinase. 
 
Role of KSR1 in cell survival 
Previous data from our lab show that TNF-induced ERK, AKT, and NF-κB activation is 
impaired in KSR1-/- colon epithelial cells.  Since ERK and NF-κB act synergistically to promote cell 
survival downstream of TNFR1 in young adult mouse colon (YAMC) epithelial cells (Yan, et al., 
2001), it is consistent that cultured KSR1-/- colon epithelial cells exhibited increased apoptosis in 
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response to TNF (Yan, et al., 2004).  The impairment in signaling is rescued by transient 
expression of wild-type KSR1 but not a kinase-inactive KSR1 mutant containing double aspartic 
acid to alanine substitutions in the kinase domain (D683A/D700A) (Yan, et al., 2004).  In addition, 
KSR1-/- mice displayed increased epithelial cell apoptosis following intraperitoneal TNF injections 
(Yan, et al., 2004).  In neuronal cells, KSR1 is required to protect against DNA damage-induced 
apoptosis by promoting ERK activation (Szatmari, et al., 2007).  Collectively, these data indicate 
that KSR1 contributes to activation of signal transduction pathways important for cell survival 
during both extrinsic and intrinsic apoptotic programs.  Since TNF is upregulated in many 
inflammatory diseases including those of the gastrointestinal tract, studying the role of KSR1 
within this context will better elucidate the function of KSR1 in health and disease. 
 
Regulation of gastrointestinal tract homeostasis 
The human digestive system is a dynamic and complex multi-organ system.  Stretching 
from mouth to anus, the gastrointestinal tract is a hollow tube where ingested food particles are 
digested, nutrients are absorbed, and waste is eliminated.  Lining the surface of the small and 
large intestine is a single cell layer of columnar epithelial cells that facilitate nutrient uptake, water 
absorption, ion transport, and barrier functions.  In the small intestine, this epithelial layer is 
maintained by stem cells that reside near the base of invaginated crypts, that divide and give rise 
daughter stem cells and proliferating progenitor cells that differentiate into four distinct lineages: 
enterocytes, entero-endocrine cells, goblet cells, or paneth cells. These cells migrate along the 
crypt-villus axis where they initiate an apoptotic program upon reaching the top of the villi and are 
ejected into the lumen (Figure 1.5).  A similar process occurs for the colonic epithelium, barring 
the presence of protruding villi and paneth cells.  Since the entire epithelial surface is renewed 
about every 5 days (Hall, et al., 1994), homeostasis requires tight regulation over proliferation, 
migration, differentiation, and apoptosis to maintain barrier integrity and protect the host from 
potentially harmful luminal contents.  When epithelial damage or ulceration occurs, the epithelial 
cells at the wound margin quickly migrate to re-establish the epithelial barrier in a process known 
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as restitution.  Simultaneously, cells of the immune system located in the sub-mucosa survey for 
and clear antigens that have penetrated the epithelial barrier.  Critical to this process are 
specialized leukocytes called dendritic cells that identify pathogenic entities and present 
processed antigens to T helper lymphocytes to initiate host defense responses as necessary (As 
reviewed in (Laffont, et al., 2009; Tezuka, et al.)).  The interplay between the epithelium and 
immune system is critical for ensuring that the host is protected from the outside world, while also 
directing immunotolerance to beneficial microbes and self-antigens.  
 
Immune function in the gastrointestinal tract 
 
Innate and adaptive immunity 
The immune system, comprised of white blood cells called leukocytes, is divided between 
two branches consisting of innate and adaptive immunity.  While functionally distinct, these two 
systems often cooperate in host defense.  Leukocytes differentiate from myeloid or lymphoid 
precursors in the bone marrow into the various immune cell types.  The innate immune system is 
comprised of neutrophils, macrophage, basophils, eosinophils, dendritic cells, and natural killer 
cells.  Often the first lines of defense, innate immune cells utilize pattern recognition receptors 
(PPRs) that recognize invariant molecular patterns common to classes of pathogens.  The 
different types of PPRs allow tailored innate responses directed towards the type of extracellular 
or intracellular pathogen.  Some PPRs are able to activate transcriptional programs including NF-
kB downstream of cell surface toll-like receptors (TLRs) and are sufficient to invoke adaptive 
immune T and B lymphocyte responses (Palm, et al., 2009). 
A specific type of leukocyte termed lymphocytes function in the adaptive immune 
response.  There are two branches of adaptive immunity comprising a humoral response 
involving B lymphocyte antibody production, and cell-mediated immunity involving macrophages, 
CD8+ cytotoxic T lymphocytes, and CD4+ helper T cells.  As the name implies, adaptive immunity  
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Figure 1.5: Regulation of gastrointestinal tract homeostasis  Separating the lumen 
from the lamina propria is a single layer of columnar epithelial cells.  This layer is 
maintained by stem cells residing near the base of the crypt that divide and give rise to 
proliferating progenitor cells.  These progenitors migrate up the crypt-villus axis where they 
undergo differentiation into absorbent enterocytes, secretory enteroendocrine, mucin 
producing goblet cells, or paneth cells (small or intestine only).  Once these cells reach the 
villus tip, they are ejected into the lumen and undergo apoptosis.  Image adapted from 
(Keller, 2007). 	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is not restricted to a defined set of genes but rather utilizes recombination of both T cell receptor  
(TCR) and immunoglobulin (Ig) to acquire antigen-specific responses.  Both TCR beta chain and 
Ig genetic loci contain multiple variable, diversity, and joining (V(D)J) gene segments that are 
rearranged through recombination, allowing for a vast repertoire of combinations (Roth, et al., 
1992).  This efficient mechanism eliminates the need to encode every possible combination within 
the genome.  Development of T cells begins in the thymus where positive and negative selection 
ensures T cells do not mount immunological responses to self-antigens, while being competent to 
recognize major histocompatibility complex (MHC) molecules during antigen presentation.  
Following this process, T cells will become activated when TCRs on naïve T cells recognize 
specific peptides presented by antigen presenting cells (APCs).  Consequently this triggers rapid 
T cell proliferation and, within days of an infection, the adaptive system mounts an effective 
defense against a specific pathogen.  Since the ERK pathway promotes T cell proliferation and 
differentiation, understanding the contribution of MAPK cascade components in these processes 
will be important to develop therapies to control aberrant T cell cytokine production associated 
with chronic inflammatory diseases (Chang, et al., 2008).  
 
Th1-Th2-Th17 
Within the CD4+ helper T cell populations there are functionally distinct subtypes, three of 
which are Th1, Th2, and Th17.  The development of naïve Th0 cell precursors into one of these 
three specific lineages depends on the type of pathogenic infection, which drives the production 
and release of small proteins called cytokines from other immune cells (Figure 1.6).  For instance, 
for Th0 cells to become polarized into Th1 cells requires the cytokine interleukin-12 (IL-12).  Th1 
cells then produce pro-inflammatory cytokines interferon-γ (IFN-γ), lymphotoxin-α (LT−α), and 
interleukin-2 (IL-2) that often cooperate with macrophage-produced tumor necrosis factor (TNF) 
to clear intracellular pathogens.  Conversely, the cytokine intertleukin-4 (IL-4) directs naïve T cells 
towards the Th2 subtype.  Th2 cells produce IL-4, interleukin-5 (IL-5), interleukin-6 (IL-6), 
17 
interleukin-10 (IL-10), and interleukin-13 (IL-13) to direct antibody production and combat 
parasitic infections.  In addition, the Th2 cytokine IL-10 counteracts the pro-inflammatory effects 
of Th1 cytokines and restricts Th1 development.  In recent years a new class of helper T cells 
was discovered in which TGFβ and IL-6 drive T cell differentiation into an interleukin-17 (IL-17) 
producing subtype termed Th17.  While the role of IL-17 in IBD is less clear, it is commonly 
associated with autoimmune diseases because of its pro-inflammatory function.  Since elevated 
cytokine production is a hallmark of inflammatory bowel disease (IBD), the balance of 
Th1/Th2/Th17 development is critical for maintaining immune homeostasis and an ideal target for 
immune modulating therapies.  
 
Inflammatory bowel disease 
The delicate balance between the appropriate immunological responses that protect the 
host, and the detrimental effects of chronic inflammation, highlight the necessity for 
understanding immune regulation.  Transient activation and expansion of leukocytes is critical for 
clearance of intracellular or extracellular pathogens through innate and/or adaptive immune 
responses.  However, sustained activation results in chronic inflammation often concurrent with 
elevated levels of cytokines and chemokines.  Diseases including rheumatoid arthritis, multiple 
sclerosis, and inflammatory bowel disease (IBD) are characterized by increased cytokines and 
dysregulated immune responses (Kalyan, et al., 2009; Pletneva, et al., 2009; Stockinger, et al., 
2007).  While the etiology of IBD is not fully understood, both genetic and environmental elements 
have been attributed to disease pathogenesis (Hampe, et al., 2001; Hampe, et al., 2007; Hugot, 
et al., 2001; Ogura, et al., 2001).  The two predominant forms of IBD affecting 1.4 million 
Americans are Crohnʼs disease and ulcerative colitis.  These two diseases are largely thought to 
result from dysregulated immunological responses to enteric antigens following epithelial 
ulceration or invading pathogens (Figure 1.7).  While both forms of IBD can present with similar 
symptoms, each disease has unique characteristics.  Originally described in 1932, Crohnʼs 
disease can  affect  any  part  of  the  gastrointestinal  tract  and  often  is discontinuous in nature 
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Figure 1.6: Differentiation of Naïve CD4+ T cells  Naïve T cells receiving a mitogenic stimulus 
differentiate along different developmental paths based on the cytokine milieu surrounding them.  
Naïve Th0 cells develop into a Th1 subtype in the presence of IL-12 and IL-2.  Th2 development 
is dependent on the presence of IL-4, whereas IL-6 and TGFβ drive Th17 differentiation.  	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(Crohn, et al., 1932).    While symptoms of ulcerative colitis have been noted for over millennia, 
Wilks and Moxon formally described the disease characteristics in 1875 following post-mortem 
examination of patients who succumbed to dysentery.  Unlike Crohnʼs disease, ulcerative colitis 
usually begins at the rectum and progresses proximally in the large intestine.  Both diseases 
involve immunological responses that largely define the condition, albeit with distinct features and 
likely varying causes.  To date there is no cure for either disease and alleviating symptoms with 
current therapeutic strategies risk long-term complication. Furthermore, for patients suffering from 
IBD, inflammation-associated carcinogenesis is increased over the course of their lifetime 
(Itzkowitz, et al., 2004).  Thus, the development of new chemical and biologic strategies that 
modulate inflammatory responses holds promise for treating patients with IBD and reducing the 
associated cancer risk.  
 
Role of cytokines in the pathogenesis of IBD  
Patients with IBD exhibit elevated levels of cytokines that are associated with disease 
pathogenesis.  Crohnʼs disease is traditionally classified as a Th1-mediated disease with 
increased TNF, IFN-γ and IL-2 (Mullin, et al., 1992; Niessner, et al., 1995), which induce tissue 
damage and epithelial apoptosis (Figure 1.7) (Francoeur, et al., 2004).  Ulcerative colitis is 
characterized as a Th2-mediated disease displaying elevated IL-6 and IL-13 that can increase 
epithelial barrier permeability and apoptosis (Funakoshi, et al., 1995; Heller, et al., 2005).  While 
IL-17 is primarily associated with autoimmune diseases including multiple sclerosis and 
rheumatoid arthritis (Kalyan, et al., 2009; Pletneva, et al., 2009; Stockinger, et al., 2007), recent 
evidence on the pathogenic effects of Th17 cells in Crohnʼs disease and ulcerative colitis has 
been described (Liu, et al., 2009).  While there is currently no cure for IBD, inhibition of TNF has 
proved to be an effective therapeutic strategy that induces remission in patients with Crohnʼs 
disease (Plevy, et al., 1997).  However, the long-term consequences of immunosuppressive 
therapies  are  not without  complications  and  side  effects.  Therefore,  identifying the molecules 
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Figure 1.7: Colon section histopathology from normal and IBD tissue Normal architecture of 
the colonic crypts resemble that of “test tubes in a rack”.  The base of the glands contacts the 
lamina propria and the top of the crypt faces the lumen.  In IBD, infiltrating granulocytes, 
macrophage, and mononuclear cells disrupt the tight arrangement of colonic glands leading to 
epithelial barrier dysfunction, translocation of luminal antigens, and infiltrating immune cells.  	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and the signaling pathways involved in regulating immunological responses are key for 
developing new therapeutic approaches for treating patients with IBD.   
 
Mouse models of IBD 
 Many human diseases such as cystic fibrosis, sickle cell anemia, Tay-Sachs disease, 
and hemophilia arise from inheritable mutations that result in disease	  (Ashley-Koch, et al., 2000; 
Bell, et al., 1995; Kerem, et al., 1989; Mahuran, et al., 1990).  Although no single gene has been 
found to be causative for IBD, mutations in NOD2 and CD39 elevate risk suggesting that multiple 
genes may be involved in disease pathogenesis (Friedman, et al., 2009; Hampe, et al., 2002).  
Technological advances in manipulation of the mouse genome have allowed for reverse genetic 
studies of protein function and have revolutionized the study of several human diseases.  In fact, 
the 2007 the Nobel Prize in Physiology or Medicine was awarded to Mario R. Capecchi, Martin J. 
Evans, and Oliver Smithies for their discoveries on genetic manipulation of mice.  In the past 20 
years, utilization of genetic deficiency mouse models including Wiskott-Aldrich Syndrome protein 
(WASP)-/-, interleukin-10 (Il10)-/-, and T cell receptor (TCR)-/-, or chemically-induced models such 
as dextran sulfate sodium (DSS) or trinitrobenzene sulfonic acid (TNBS) have been used to study 
IBD since these mouse models develop characteristics similar to human IBD.  While no one 
model fully recapitulates human IBD, insight into the molecules involved in inflammation, tissue 
damage, and epithelial restitution has been learned (As reviewed in (Hibi, et al., 2002)).  
Identifying the mechanisms that drive disease in animal models may yield new therapeutic targets 
and strategies to treat patients with IBD and is worthy of further investigation.     
 
Interleukin-10 deficiency model of colitis 
One cytokine involved in immune homeostasis and suppresses the activity of Th1 
responses is IL-10 (Fiorentino, et al., 1989; Maynard, et al., 2007).  It is known that decreased IL-
10 levels are associated with IBD and recently polymorphisms were found in the IL-10 receptor 
locus of IBD patients (Glocker, et al., 2009; Ishizuka, et al., 2001).    Consistent
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Figure 1.8:  Effects of cytokines in IBD pathogenesis  For patients with IBD, dysregulated 
innate and adaptive immune responses to commensal luminal flora lead to epithelial barrier 
breakdown.  A) Bacterial translocation resulting from increased barrier permeability in Crohnʼs 
disease.  B) Hyperactive immune responses trigger cytokine and chemokine release that then 
recruit and activate additional immune cells.  C) Persistent elevation of cytokine levels, including 
TNF and IFN-γ, result in additional epithelial cell apoptosis and increased barrier permeability.  
Image adapted from (Gil, 2008). 	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with an immunosuppressive role for IL-10, Il10-/- mice develop spontaneous enterocolitis as a 
result of dysregulated immune responses to enteric microbial antigens (Kühn, et al., 1993). 
Disease progression and penetrance in Il10-/- mice is highly dependent on mouse strain and 
vivarium conditions.  Since IL-10 deficiency-induced colitis is a Th1-mediated disease responsive 
to anti-TNF therapy, it is considered a valid model for studying human Crohnʼs disease (Rennick, 
et al., 1995; Scheinin, et al., 2003).  Unfortunately, administration of recombinant IL-10 to IBD 
patients has not proven to be a successful therapeutic strategy.  Thus, the need for identifying 
other immunomodulatory molecules that can influence Th1-mediated diseases including Crohnʼs 
disease is necessary (Li, et al., 2004).    
 
Dextran sulfate sodium (DSS) model of colitis 
 Another mouse model developed for studying IBD is the chemically induced DSS model 
of colitis (Okayasu, et al., 1990). DSS is routinely administered via the drinking water at a 
concentration ranging from 2.5-5% (v/v) over a period of several days.  While the efficacy for 
inducing colitis with DSS is highly strain dependent as well (Mahler, et al., 1998), the resulting 
ulcerations are characterized by epithelial cell loss and increases in barrier permeability	   (Cario, 
2005).  This disruption in epithelial barrier results in mucosal immune activation and the 
recruitment of neutrophils, macrophage, and lymphocytes, which promotes the release of pro-
inflammatory cytokines including TNF (Dieleman, et al., 1998).  Unlike other models of IBD, DSS-
induced colitis exhibits both Th1 and Th2 cytokine profiles depending on the stage of disease 
(Dieleman, et al., 1998).  While DSS is able to induce colitis in Rag2-/- mice, abrogating a 
requirement for the adaptive arm, Th1 cytokines exacerbate disease pathogenesis in the DSS 
model (Dieleman, et al., 1994; Kim, et al., 2006).  The DSS model is a powerful tool to investigate 
the acute and chronic phases of disease as well as epithelial restitution due to its ulcerating 
effects.        
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Objectives 
Previous work from our lab and others demonstrate that immunoprecipitated KSR1 
phosphorylates and activates Raf in vitro (Yan, et al., 2004; Zafrullah, et al., 2009; Zhang, et al., 
1997).  In addition, expression of kinase-inactive KSR1 in YAMC cells sensitizes cells to TNF-
induced apoptosis in vitro (Yan, et al., 2001).  However, interpreting data from in vitro kinase 
assays using immunoprecipitated KSR1 proteins is inconclusive since KSR1 associates with 
several known protein kinases.  To date there have been no published data demonstrating that 
bacterially expressed recombinant KSR1 possesses kinase activity.  Furthermore, since KSR1-/- 
mice have increased apoptosis in colon epithelial cells following TNF treatment (Yan, et al., 
2004), and TNF levels are increased in patients with IBD, the role of KSR1 in inflammatory 
disease warrants further investigation.  The first objectives of this study were to determine if 
KSR1 possesses catalytic activity by expressing and recovering KSR1 from E. coli, a system 
devoid of serine/threonine protein kinases.  Secondly, we investigated the role of KSR1 during 
chronic inflammation using the Il10-/- mouse model of spontaneous enterocolitis.  
To test the hypothesis that KSR1 is a functional protein kinase (Chapter III), we 
established a bacterial expression system in E. coli and recovered recombinant KSR1 (rKSR1).  
In vitro kinase assays utilizing [γ-32P]ATP were performed on rKSR1 to screen for intrinsic kinase 
activity.  Kinase assays were also performed assessing the ability of mammalian KSR1 and 
recombinant KSR1 to phosphorylate bacterially expressed recombinant MEK.  We also examined 
if KSR1 kinase activity towards MEK promoted epithelial cell survival in response to TNF.  
The second objective of this study was to investigate the role of KSR1 during chronic 
inflammation.  We tested the hypothesis that KSR1 is protective against a mouse model of colitis 
by promoting epithelial cell survival (Chapter IV).  To do this we crossed a KSR1-/- mouse to the 
Il10-/- mouse model of spontaneous colitis.  Mice were examined for external and histological 
signs of colitis.  Changes in epithelial cell turnover were determined by immunohistochemical 
staining for apoptotic and proliferative markers.  Bone marrow transplants were performed to 
determine if KSR1 functioned in the immune system to suppress colitis.  Primary lymphocytes 
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were isolated and assayed for Th1/Th17 polarization defects in vitro.  Neutralizing antibodies 
were administered intraperitoneally to investigate the involvement IFN-γ and IL-17A in KSR1-/-Il10-
/- disease pathogenesis.   We also examined the role of KSR1 in a second model of Th1-mediated 
colitis using DSS.  
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CHAPTER II 
 
MATERIALS AND METHODS 
 
Cell culture and generation of cell lines 
 
Culture conditions and procedures  
The conditionally immortalized KSR1-/- colon epithelial cell line was generated by crossing 
a KSR1-/- mouse with the H-2Kb–tsA58 ImmortoMouse (Charles River Laboratories International 
Inc., Wilmington, MA), as previously described (Corredor, et al., 2003; Whitehead, et al., 1993; 
Yan, et al., 2004). Conditionally-immortalized colon epithelial cell lines were maintained under 
permissive conditions consisting of 5 units/ml of murine interferon-γ (BD Bioscience, San Jose, 
California) at a temperature of 33º C 5% CO2 in RPMI 1640 (Mediatech, Manassas, VA) 
supplemented with 5% FBS (Atlanta Biologicals, Lawrenceville, GA), 100 units/mL penicillin and 
streptomycin (Invitrogen, Carlsbad, California), 5 mg/mL insulin, 5 mg/mL transferrin, 5 mg/mL 
selenous acid (ITS) (BD Bioscience).  Prior to each experiment, cells were placed overnight at 
non-permissive conditions at 37o C 5% CO2  in RPMI 1640 containing 0.5% FBS, 100 units/mL 
penicillin and streptomycin, and without interferon-γ.  
 
Retroviral infections 
Murine wild-type KSR1 or murine KSR1D683A/D700A, both FLAG-tagged at the N-terminus, 
were a generous gift from Richard Kolesnick (Memorial Sloan-Kettering Cancer Center, New 
York, NY).  These constructs were subcloned into the bicistronic pLZRS-IRES-GFP retroviral 
vector and transfected into Phoenix 293 ecotropic viral packaging cells.  Viral supernatants were 
collected and KSR1-/- colon epithelial cells were infected with virus containing empty vector 
(+vector), FLAG-tagged wild-type KSR1 (+KSR1), or FLAG-tagged KSR1D683A/D700A 
(+D683A/D700A).  Infected cells were then sorted based on GFP expression by fluorescence-
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activated cell sorting (FACS).  Sorted cell lines were screened for KSR1 protein expression and 
those expressing near endogenous levels of KSR1, when compared to young adult mouse colon 
(YAMC) epithelial cells, were used for subsequent cell culture experiments.  
  
Cell lysate preparation 
 
Cell lysis and immunoprecipitation  
 Cell lysates were prepared by washing adherent cells in ice cold PBS followed by 
scraping cell into cell lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 1 mM EDTA, 1% Triton X-
100, and 0.1% protease and phosphatase I and phosphatase II inhibitor cocktails (Sigma) on ice.  
Total cell lysates were analyzed for protein concentration, boiled in Laemmli sample buffer at 95º 
C for 5 minutes, separated by SDS-PAGE, and analyzed by Western blot analysis.  For 
immunoprecipitations, 30 µl of agarose-linked anti-FLAG M2 antibody (Sigma) were washed 3X in 
TBS (50 mM Tris pH 7.4, 150 mM NaCl) followed by a final wash in cell lysis buffer.  Unless 
specifically stated, immunoprecipitations were performed on whole cell lysate from 1 mg of total 
protein and rocked overnight at 4º C.  Immunoprecipitates were washed 3X in lysis buffer, boiled 
in 30 µl Laemmli sample buffer at 95º C for 5 minutes, and analyzed by Western blot analysis.                                                                  
 
SDS-PAGE and Western blot analysis 
Whole cell lysates or immunoprecipitated proteins were separated on 10% SDS-
polyacrylamide gel electrophoresis (PAGE) and transferred to nitrocellulose.  Membranes were 
blocked in 5% non-fat dry milk in TBS-Tween (0.05%) (TBST) at room temperature for 1 hour, 
washed in TBST, and incubated in primary antibody at room temperature for 1 hour.  Membranes 
were then washed for 5 minutes 3X in TBST, incubated with the appropriate HRP-conjugated 
secondary antibody for 1 hour at room temperature, and washed for 5 minutes 3X in TBST.  Total 
and phospho-proteins were detected by chemiluminescence using a luminol HRP substrate.  
Antibodies used in these studies include: KSR1 (BD Bioscience, #611577), KSR1 C-terminus 
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(Santa Cruz Biotechnology, #sc-1837, Santa Cruz, CA) Raf-1 (Santa Cruz Biotechnology, #sc-
133), B-Raf (Santa Cruz, #sc-166), MEK1/2 (Cell Signaling, #9122, Danvers, MA), phospho-
MEK1/2 (Cell Signaling, #9121), ERK1/2 (Cell Signaling, #4695), phospho-ERK1/2 (Promega, 
#V803A, Madison, Wisconsin), phospho-p38 (Cell Signaling, #9211), p38 (Cell Signaling, #9212), 
actin (Sigma). 
 
Recombinant protein expression 
FLAG-tagged wild-type KSR1 (rKSR1), FLAG-tagged kinase-inactive KSR1 
(rD683A/D700A), FLAG-tagged rKSR1DCA1, HA-tagged wild-type KSR1 kinase domain 
(rKSR1ΔN521), FLAG-tagged wild-type Raf-1 (rRaf-1), FLAG-tagged kinase-inactive Raf-1 (rRaf-
1 K375M), and His-tagged kinase-inactive (rMEK K97M) constructs were cloned into the pET 30 
bacterial expression vector and were transformed into E. coli BL21(DE3) (Novagen).  Protein 
expression was induced upon the addition of 0.1 mM Isopropyl β-D-1-thiogalactopyranoside 
(IPTG) overnight at 25º C.  Bacteria were lysed using CelLytic B Plus Kit (Sigma, St Louis, MO) 
following the manufacturerʼs protocol. Recombinant KSR1 and Raf-1 proteins were recovered 
from insoluble inclusion bodies under denaturing conditions using 8 M urea and dialyzed into 
buffer (50 mM Tris pH 7.4, 100 mM NaCl).  His-MEK K97M protein expression was induced as 
before and bacteria supernatant containing recombinant proteins were purified using Ni-MAC 
column according to the manufactures protocol (Novagen). 
 
In vitro kinase assays 
 
MEK phosphorylation assay 
FLAG immunoprecipitates from KSR1 expressing cells lines were washed 3X in lysis 
buffer containing 1 M NaCl, equilibrated in kinase assay buffer (20 mM MOPS pH 7.2, 25 mM β-
glycerophosphate, 5 mM EGTA) (Millipore) for 20 minutes, then incubation with rMEK K97M in 
the presence Mg2+/ATP (Millipore) at 30º C for 30 minutes.  The kinase reaction was stopped 
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upon addition of Laemmli sample buffer and heated to 95º C for 5 minutes.  Western blot analysis 
was performed on separated samples to determine MEK phosphorylation.  For in vitro kinase 
assays using recombinant proteins, rMEK K97M was incubated with rKSR1, rD683A/D700A, or 
rRaf-1 proteins as before at 30º C for 30 minutes.  The kinase reaction was stopped upon addition 
of Laemmli sample buffer and heated to 95º C for 5 minutes.  Samples were then analyzed by 
Western blot analysis.  
 
KSR1 autophosphorylation assay 
In vitro kinase assays were performed on rKSR1 and rD683A/D700A in the presence of 
10 µCi [γ-32P]ATP (Perkin-Elmer, Waltham, Massachusetts) at 30º C for 30 minutes.  The kinase 
reaction was stopped upon addition of Laemmli sample buffer and heated to 95º C for 5 minutes. 
Samples were separated using SDS-PAGE, transferred to PVDF membrane, and incorporation of 
32P was assayed by autoradiography.  Total KSR1 protein was then determined by Western blot 
analysis.   
 
KSR1 Phosphoamino acid analysis 
Following autoradiography, PVDF bound 32P-KSR1 was excised and amino acids were 
hydrolyzed using 6 M HCl at 110º C for 1 hour.  Amino acids were then lyophilized and 
rehydrated with pH 1.9 buffer containing PAA standards.  Amino acids were spotted at a single 
origin on a TLC plate and were run in the first dimension at 1500 V for 25 minutes.  The TLC plate 
was then rotated 90º and run in the second dimension in pH 3.9 buffer at 1300 V for 20 minutes.  
The TLC plate was dried and then sprayed with 0.25% Ninhydrin solution and incubated at 100º 
C until PAA standards were detectable by development of Ruhemann's purple (Duclos, et al., 
1991).  rKSR1 32P-phosphoaminio acids were determined via autoradiography and aligning the 
exposed Kodak BioMax film against the Ruhemann's purple phosphoamino acid standards visible 
on the TLC plate. 
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KSR1 2D-phosphopeptide mapping 
Briefly, following an in vitro kinase assay using [γ-32P]ATP and exposure to film, the 32P-
rKSR1 was excised from the PVDF membrane and MeOH was added to wet to the membrane.  
The PVDF membrane was then incubated at 37º C for 30 minutes in 50 mM NH4HCO3 containing 
0.1% Tween-20.  Following incubation, membrane was rinsed 5X with H2O, 2X with 50 mM 
NH4HCO3 buffer, then resuspended in 200 µl NH4HCO3 buffer containing 10 µg trypsin and 
digested for 3 hours at 37º C.  Following digestion, 400 µl water was added, vortexed, and spun 5' 
at 13k RPM.  Supernatant was removed and lyophilized in speed-vac. Lyophilized sample was 
resuspended in 400 µl of pH 1.9 buffer and lyophilized again. Lyophilized sample was 
resuspended in 6 µl of pH 1.9 buffer and spotted on the origin of a pre-marked TLC plate and 
subjected to electrophoresis at 1000 V for 30 minutes.  TLC plate was dried and placed in a 
chromatography buffer (75 vols. n-Butanol, 50 vols. pyridine, 15 vols. acetic acid, and 60 vols. 
water) chamber overnight oriented such that migration in the second dimension is towards the top 
of the glass.  TLC plate was dried and phosphopeptides determined by autoradiography. 
 
MBP phosphorylation assay 
MBP phosphorylation assays were performed using the MBP Kinase Flex Assay Kit 
(Millipore) with rKSR1, rD683/D700A, rKSR1ΔN521, rRaf-1, or rRaf-1 K375M proteins following 
manufactures protocol.  Whole cell lysates from EGF treated YAMC cells were used as a positive 
control for MBP phosphorylation.  Relative MBP phosphorylation was calculated by comparing 
recombinant proteins incubated with  MBP  to   MBP  phosphorylation  when   no  additional 
recombinant proteins were present (MBP only).  
 
MEK activation assay 
In vitro MEK activation assay with recombinant KSR1 proteins were conducted using 
unactive recombinant wild-type MEK1 (rMEK) (Millipore), and recombinant kinase-dead ERK2 
(rERK) (Millipore) incubated for 30 minutes at 30º C.  Kinase reaction was stopped by the addition 
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of Laemmli sample buffer and boiled for 5 minutes at 95º C.  Total and phospho-proteins were 
determined by Western blot analysis.  For in vitro MEK activation assays utilizing 
immunoprecipitated FLAG-KSR1, FLAG-D683A/D700A, and FLAG-Raf-1 proteins, KSR1 and 
Raf-1 immunoprecipitated protein concentrations were determined using linear regression based 
on Western blot analysis of a standard curve with FLAG-BAP (Sigma), for KSR1 determination, or 
recombinant Raf-1 (Millipore), for Raf-1 determination.  FLAG-KSR1 and FLAG-D683A/D700A 
were immunoprecipitated from 1 mg of whole cell lysate to obtain 1 pmol KSR1 protein.  FLAG-
Raf-1 was immunoprecipitated form 0.6 mg of whole cell lysate to obtain 1 pmol Raf-1 protein.  
Immunoprecipitated proteins were washed 3X in cell lysis buffer containing 1M NaCl.  
Immunoprecipitates were then washed 1X with lysis buffer and equilibrated in kinase assay buffer 
for 20 minutes at 4º C.  Samples were incubated with 0.5 pmol rMEK1 and 1 pmol rERK in the 
presence of ATP/Mg2+ in assay dilution buffer (ADB) for 30 minutes at 30º C.  MEK activity was 
determined by Western blot analysis using an anti-phospho-ERK antibody (Promega).  
 
Cell loss assays 
 
TUNEL assay 
Cell lines expressing +vector, +KSR1, and +D683A/D700A were seeded in 4-well 
chamber slides at 5x104 cells (4-well chamberslide, Lab-Tek), and placed under non-permissive 
conditions overnight prior to experiments.  Cells were then treated with 100 ng/ml murine TNF 
(Peprotech, Rocky Hill, NJ) for 8 hours.  Apoptotic cells were labeled using terminal 
deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) (Millipore, Billerica, MA) following 
the manufacturerʼs protocol.  The percentage of TUNEL positive cells was determined for a 
minimum of 500 cells counted using differential interference contrast microscopy at 20X 
magnification.  
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Nucleocount assay 
6-well dishes were seeded at 4x105  cells/well and maintained under permissive 
conditions for 24 hours.  Following 16 hours under non-permissive conditions, cells were then 
pre-treated with vehicle (DMSO) or 10 µM of U0126 (MEK kinase inhibitor) (Calbiochem, 
Darmstadt, Germany) for 45 minutes followed by 100 ng/ml TNF for 24 hours.  Cells were then 
washed 3X in PBS, incubated in cell lysis buffer, and the total number of adherent cells was 
determined by counting propidium iodide stained nuclei using a NucleoCounter (New Brunswick 
Scientific, Edison, New Jersey).  Cell loss was calculated by comparing 24-hour treated cell 
numbers to 24-hour untreated control.  
 
Animals 
 
Generation of mice  
KSR1-/- mice were crossed with Il10-/- mice to generate KSR1-/-Il10-/- mice.  Since KSR1-/-
Il10-/- female mice did not produce litters, maintenance of the colony required a breeding strategy 
using KSR1-/-Il10-/- male mice mated with KSR1-/-Il10+/- female mice.   BALB/c (WT), KSR1-/-, Il10-/-
, and KSR1-/-Il10-/- mice were bred and maintained on a BALB/c background, conventionally 
housed under SPF conditions, and fed a standard rodent chow diet.  Rag2-/- mice (BALB/c) were 
purchased from Taconic and housed in autoclaved cages and fed autoclaved rodent chow 
(Albany, NY). 
 
Conformation of genotype 
 Alleles corresponding to targeted disruption in the Il10 or KSR1 loci were confirmed by 
PCR using isolated genomic DNA from tail clippings obtained by digesting mouse tails in 
DirectPCR (Tail) buffer (Viagen Biotech, Inc., Los Angeles, CA) containing 250 µg/ml proteinase 
K (MACHEREY-NAGEL, Germany) overnight at 55º C followed by a 1-hour incubation at 85º C.  
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PCR was performed on genomic DNA to confirm the presence of wild-type or knock-out alleles for 
Il10 and/or KSR1 using specific primers and corresponding PCR program outlined in Table 1. 
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Histological assessment 
Mice were sacrificed by administration of CO2 followed by cervical dislocation.  Mouse 
colon and small intestine were harvested and “swiss-rolled”, fixed in 10% formalin, and embedded 
in paraffin blocks. 5 µm sections were mounted and stained with Hematoxylin and Eosin (H&E).  
Histology was scored for inflammation and injury by M.K.W. who was blinded to the genotypes 
and/or treatment conditions based on a scoring method previously described (Kennedy, et al., 
2000). 
 
Administration of treatment 
 
Azoxymethane (AOM) 
 6-week old mice were administered a single intraperitoneal injection of 12.5mg/kg AOM. 
 
Cytokine neutralization 
 3-week old KSR1-/-Il10-/- mice were given intraperitoneal injections of 100 µg/mouse anti-
IgG (eBioscience, cat#16-4301, San Diego, CA), anti-IFN-γ (eBioscience, clone XMG 1.2), or anti-
IL-17A (eBioscience, clone: eBioTC11-18H10.1) neutralizing antibodies twice per week for 3 
weeks.  Mouse colons were harvested and scored for inflammation and injury by Vanderbilt 
pathologist M.K.W.  
 
Dextran sulfate sodium (DSS) 
Mice were placed in cages where regular drinking water was replaced with water 
containing 3% (w/v) DSS (36–50 kilodaltons; MP Biomedicals, Solon, OH) for 7 days.  Subsets of 
mice were given regular drinking water for a period of 4 days following DSS treatment to 
determine the ability to recover from injury.   Mice were monitored daily for changes in weight as 
well as tested for fecal occult blood (Hemoccult; Beck- man Coulter, Fullerton, CA).  Following 
DSS or the recovery period, mice were sacrificed, colons removed, fixed in 10% formalin, and 
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embedded in paraffin blocks.  5 µm sections were cut and stained with H&E and colon histology 
was scored by pathologist M.K.W. based on a method for DSS-induced injury previously 
described (Dieleman, et al., 1998).   
 
Immunohistochemistry 
Mouse colon sections were de-paraffinized, rehydrated, and antigen unmasked by boiling 
in a citrate-containing buffer (Vector Laboratories, Burlingame, CA).  Slides were blocked with 
10% goat serum (Zymed Laboratories Inc., Carlsbad, CA) for 30 min and proliferation was 
assayed by staining with Ki67 (Lab Vision, Fremont, CA) or phospho-histone-H3 (Cell Signaling, 
Boston, MA) antibody at 4° C overnight.  Slides were washed and incubated with anti-rabbit 
horseradish peroxidase (Dako, Denmark) for 30 minutes.  HRP-conjugated secondary were 
developed using a DAB substrate kit (Vector Laboratories), counterstained with Hematoxylin and 
viewed using a Nikon Eclipse E800 microscope.  Apoptotic cells were detected by in situ 
oligonucleotide ligation (ISOL) (Chemicon, Billerica, MA) or terminal deoxynucleotidyltransferase 
nick-end labeling (TUNEL) peroxidase staining (Chemicon) following the manufactureʼs protocol 
and viewed using a Nikon Eclipse E800 microscope. 
 
Barrier permeability 
Mice were sedated for 30 minutes using a single intraperitoneal injection of ketamine (5 
mg/ml)/xylazine (0.5 mg/ml) solution (100 µl/10g body weight).  Fluorescein-dextran (Sigma cat# 
FD4, St. Louis, MO) (0.6 mg/gram mouse weight) was administered per rectum using a 3.5 Fr 
catheter.  Peripheral blood was collected 30 minutes later and serum fluorescence was measured 
using a fluorescent plate reader and compared to preinjection serum fluorescence concentration 
using linear regression analysis using a FITC-dextran concentration standards. 
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Bone marrow transplantation 
3-week old WT or KSR1-/-Il10-/- recipient mice were placed on water containing neosporin 
G.U. irrigant (Monarch Pharmaceuticals, Bristol, TN) 1 week prior to irradiation. Recipient mice 
were given a single total body lethal dose of 9 Gy from a 137Cs γ-radiation source 5 hours prior to 
transplant.  Bone marrow was isolated from femurs of WT, KSR1-/-, Il10-/-, or KSR1-/-Il10-/- donor 
mice and 5 x106 bone marrow cells/mouse were injected via the retro-orbital venus plexus of 
irradiated recipients.  For transplantation of KSR1-/-Il10-/- bone marrow into KSR1-/-Il10-/- 
recipients, sex mismatched male donor cells were injected into female recipients and engraftment 
was screened by PCR to detect the male SRY gene locus.  Mice were sacrificed 6 weeks post-
transplant and colitis assessed by scoring colon inflammation and injury as before.  
 
Leukocyte differentiation 
Mouse peripheral blood was drawn from the saphenous vein and collected in heparin 
coated Microvette tubes (Sarstedt, Germany).  Blood was analyzed using a HemaVet 950FS 
(Drew Scientific Inc., Dallas  TX).  Leukocyte populations were recorded as percentage of total 
leukocytes. 
 
T cell proliferation 
Primary T cells were isolated from the spleens of mice.  Red blood cells were lysed and 2 
x 105 cells in RPMI 1640 media containing 10 mM HEPES (Sigma, St Louis, MO), 10 µg/mL 
gentamycin (GIBCO, Carlsbad, CA), 100 U/mL penicillin/100 µg/mL streptomycin (GIBCO) and 
10% heat-inactivated FBS (Atlanta Biologicals, Lawrenceville, GA) were seeded in round bottom 
96-well plates pre-coated with 5 µg anti-CD3ε (BD Bioscience cat # 557306, San Jose, CA) and 5 
µg anti-CD28 (BD Bioscience cat # 557393).  Cells were grown for 72 hours at 37° C then pulsed 
for 18 hours with 1 µCi/well [3H]thymidine (ICN, Solon, OH).  Incorporated [3H]thymidine was 
detected using a TopCount plate reader (Perkin Elmer, Waltham, MA). 
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Colonic cytokine profiling 
 
RNA isolation and quantitative real-time PCR analysis 
Total RNA was collected from whole mouse colons that were flushed of contents with ice-
cold PBS, homogenized and lysed on ice, and purified using Qiagen RNA isolation kit and treated 
with RNase-free DNase as directed (Qiagen, Valencia, CA).   Reverse transcription was 
performed using the High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Foster 
City, CA).  For real-time RT-PCR, we used the relative gene expression method (Giulietti, et al., 
2001).  GAPDH served as the normalizer.  All cDNA samples were analyzed in triplicate, along 
with "no reverse transcriptase" controls, using Applied Biosystems 7000 or Step One Plus real-
time PCR instruments.  Levels of cytokine expression are indicated as relative units, based on 
comparison of RNA pooled from 6 WT mouse colons (calibrator tissue) (Giulietti, et al., 2001).  
Primer and probe sets were purchased as Taqman Gene Expression Assays (Applied 
Biosystems). 
 
Intracellular cytokine staining 
 
Flow cytometry reagents 
 Fluorochrome coupled anti-CD4, -CD45RB, -TCRb, -IFN-γ, and anti-IL-17 as well as 
unconjugated anti-CD3, -CD28, -IFN-γ, -IL-4 and rmIL-6 were all purchased from BD Pharmingen 
(San Jose, CA).  rhTGF-β1 was purchased from R&D Systems (Minneapolis, MN). 
 
Generation of Th17 and Th1 cells in vitro 
    Th17 cells were generated as described (Lee, et al., 2009) with some modifications. 
Briefly, total splenocytes were lysed of red blood cells and plated at a density of 2.5x106 cells per 
well (12-well plate) in RPMI containing 10% FCS in the presence of plate-bound anti-CD3 (5 
µg/ml), soluble anti-CD28 (2.5 µg/ml), anti-IFN-γ (10 µg/ml), anti-IL-4 (10 µg/ml), rhTGF-β1 (5 
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ng/ml), rmIL-6 (20 ng/ml), and supplemented with sodium pyruvate and non-essential amino 
acids. Two days after culture, cells received 1 ml of fresh medium containing anti-IFN-γ, anti-IL-4, 
rhTGF-β1, rmIL-6, sodium pyruvate, and non-essential amino acids.  At day 6, cells were 
analyzed for cytokine production.  Th1 cells were generated by using same isolation as above, 
cultured in RPMI containing 10% FCS in the presence of plate-bound anti-CD3 (5 µg/ml), soluble 
anti-CD28 (2.5 µg/ml), anti-IL-4 (10 µg/ml), IL-2 (20 units/ml), IL-12 (5 ng/ml), supplemented with 
sodium pyruvate and non-essential amino acids, and analyzed as before on day 6. 
 
Naïve T cell activation 
 Primary splenocytes were isolated and single cell suspensions were incubated with 
PMA/Ionomycin (20 ng/ml and 1 µM respectively) and GolgiPlug (BD Biosciences) for 5 hours. 
Cells were then washed and stained with the appropriate surface markers. After fixing, cells were 
washed with Perm/Wash solution (BD Biosciences) followed by intracellular staining with anti-
cytokine antibodies. Cells were acquired in a FACSCalibur instrument and data analyzed using 
FlowJo software (Tree Star, Inc., Ashland, OR). 
 
Adoptive transfer of colitogenic T cells 
Total splenocytes from donor mice were cleared of red blood cells by lysis in sterile water 
briefly then brought up in RPMI 1640 media and depleted of B cells using magnetic beads and 
columns as described by the manufacturer (Miltenyi, Germany). Cells were stained with anti-CD4 
APC and anti-CD45RB FITC and sorted to obtain a fraction (~99% purity) of CD4+CD45RBhigh 
cells as previously described (Powrie, et al., 1994). Sorted cells were thoroughly washed with 
sterile PBS and 0.75 x 106 cells were adoptively transferred, i.v. per recipient Rag2-/- mice.  Hosts 
were followed twice a week for weight change and signs of colitis, such as diarrhea, rectal 
bleeding, and scruffiness.  
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Lymphocyte isolation 
Splenocytes and cells from mesenteric lymph nodes were isolated using conventional 
procedures. Colon IEL and lamina propria lymphocytes were obtained as previously described 
(Olivares-Villagómez, et al., 2008). Briefly, colons were dissected and the intestinal content 
flushed out with cold Hanks' balanced salt solution (HBSS). Colons were cut into 0.5 cm pieces 
and incubated with medium force shaking (~200 rpm) for 30 minutes in HBBS/5% FCS at 37° C.  
Supernatant was recovered, filtered through a glass wool column and after washing, IEL were 
separated in a 70% - 40% Percoll discontinuous gradient. The remaining tissue was incubated 
again for 30 minutes as before in HBSS/5% FCS/2mM EDTA.  Supernatant was discarded and 
the tissue was cut into smaller pieces and digested for 20 minutes at 37° C in 5ml of HBSS/5% 
FCS containing 1.5 mg/ml collagenase VIII (Sigma) and 100 units of bovine pancreatic DNase I 
(Sigma).  The slurry was filtered and collected, and the tissue was again digested in fresh 
medium for an additional 20 minutes. Slurries were pooled, washed and lamina propria cells were 
resuspended in fresh medium. 
 
Statistical analysis 
For the experiments involving KSR1-MEK binding and cell loss assays, a one-way 
analysis of variance (ANOVA) model was used to determine significance.  The P value was 
adjusted for multiple comparisons with the Dunnettʼs post-test using a 95% confidence interval for 
three independent experiments. Histopathology, immunohistochemistry, and qRT-PCR statistical 
analysis were compared using one-way ANOVA followed by Dunnettʼs post-test.  Bone marrow 
transplant, Th1/Th17 polarization, intracellular cytokine staining and cytokine neutralization 
statistical analysis were performed using an unpaired Studentʼs t test.  P­values of ≤ 0.05 were 
considered significant.  All data was analyzed using Prism 5 (GraphPad Software, Inc.).  
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CHAPTER III 
 
KSR1 IS A FUNCTIONAL PROTEIN KINASE CAPABLE OF SERINE 
AUTOPHOSPHORYLATION AND DIRECT PHOSPHORYLATION OF MEK1 
 
Introduction 
Many cellular responses to external stimuli utilize MAPK pathways to carry out a diverse 
range of biological processes.  Activation of these pathways, which are conserved in all 
eukaryotes, is often initiated by GTPases downstream of cell surface receptors, followed by 
sequential signal transduction through a three-component kinase system.  One particular MAPK 
module consists of the protein kinases Raf, MEK, and ERK.  Canonical activation of the 
Raf/MEK/ERK cascade occurs downstream of the small GTPase Ras to elicit a variety of cellular 
responses including proliferation, differentiation, and cell survival (Cheng, et al., 2008; Kaiser, et 
al., 1999; Kanakura, et al., 1991; Qui, et al., 1992).  Since the ERK pathway is integral for many 
cellular events, and constitutive pathway activation is frequently concurrent with many cancers, 
understanding the precise mechanisms that contribute to pathway activation are essential for 
developing therapeutic targets that modulate this pathway (Andreyev, et al., 2001).  KSR1, first 
identified through genetic screens in D. melanogaster and C. elegans, is an evolutionarily 
conserved protein that positively regulates the Raf/MEK/ERK cascade by functioning either 
upstream or in parallel with Raf-1 (Kornfeld, et al., 1995; Sundaram, et al., 1995; Therrien, et al., 
1995).  KSR1 functions as a molecular scaffold by binding several signaling components of the 
ERK cascade; and thus can enhance MAPK activation by regulating the efficiency of these 
interactions (Denouel-Galy, et al., 1998; Stewart, et al., 1999; Yu, et al., 1998).  In addition to its 
scaffolding role, there is evidence that KSR1 functions as a protein kinase.  The KSR1 C-terminus 
contains the twelve subdomains that are conserved in all protein kinases including the conserved 
aspartic acid and asparagine residues within subdomain VIb (HRDLKxxN motif) and the aspartic 
acid in subdomain VII (DFG motif) (Hanks, et al., 1995; Hanks, et al., 1988).  However, the 
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catalytic function of KSR1 remains controversial since mammalian KSR1 contains an arginine in 
place of the invariant lysine residue in subdomain II.  This lysine positioned in subdomain II is 
involved in binding and orienting the ATP molecule to facilitate phosphotransfer of ATP γ-
phosphate (Kamps, et al., 1986).  While lysine to arginine mutations in this position disrupt ATP 
binding and render many protein kinases inactive (Cotten, et al., 2003; Ebina, et al., 1987; Gibbs, 
et al., 1991; Snyder, et al., 1985), a KSR1 splice variant is able to bind ATP when the arginine 
was substituted with lysine or methionine	   (Müller, et al., 2000).  This suggests that KSR1 might 
utilize a different lysine, as seen with the protein kinase with no lysine-1 (WNK1) (Xu, et al., 
2000), or may have a structurally unique ATP-binding cleft compared to other protein kinase 
domains. Therefore, further investigation into KSR1 catalytic function is warranted. 
Initial reports of KSR1 protein kinase activity suggest that immunoprecipitated KSR1 
autophosphorylates, as well as phosphorylate and activate Raf-1, in vitro (Xing, et al., 2000; Yan, 
et al., 2004; Zhang, et al., 1997).  However, immunoprecipitated KSR1 contains additional co-
precipitating protein kinases making it difficult to delineate KSR1 protein kinase activity from that 
of other contaminating kinases in the assay (Michaud, et al., 1997; Volle, et al., 1999).  Therefore, 
to resolve KSR1 kinase activity from other protein kinases in vitro requires isolating recombinant 
proteins expressed in a system with no known serine/threonine protein kinases, such as E. coli 
(Rahmsdorf, et al., 1974).   
Here we report that bacterially-derived KSR1 underwent serine autophosphorylation, 
phosphorylated myelin basic protein (MBP) as a generic substrate, and phosphorylated 
recombinant kinase-inactive MEK1 (rMEK K97M).  We also demonstrate that both a functional 
KSR1 kinase domain and MEK protein kinase activity are required for resistance to TNF-induced 
cell death in colon epithelial cells.  Taken together, these data indicate that in addition to a 
scaffold, KSR1 is indeed a functional protein kinase in the ERK pathway downstream of TNF 
signaling. 
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Results 
 
KSR1 protection from TNF-induced cell death requires a functional KSR1 kinase domain and 
MEK kinase activity.  
The pleiotropic pro-inflammatory cytokine, tumor necrosis factor, (TNF) elicits various 
cellular responses in a variety of cell types in vitro and in vivo and plays a pivotal role in chronic 
gastrointestinal disorders including celiac and inflammatory bowel diseases (Breese, et al., 1994; 
Kontakou, et al., 1994; Zhou, et al., 2008).  Previous studies from our lab show that the colon 
epithelium of KSR1-/- mice is sensitive to TNF-induced apoptosis compared to wild-type mice 
(Yan, et al., 2004).  Therefore, to determine if KSR1 kinase activity is required to prevent TNF-
induced cell death, we produced stable KSR1-/- colon epithelial cell lines expressing either empty 
vector (+vector), FLAG-tagged wild-type KSR1 (+KSR1), or FLAG-tagged kinase-inactive KSR1 
containing alanine substitutions at aspartic acid residues in the HRDLKxxN and DFG motifs 
involved in phosphotransfer (+D683A/D700A) via retroviral infection with bicistronic GFP 
expression constructs.  These cells were then sorted based on GFP expression to obtain lines 
expressing KSR1 at near endogenous levels compared to YAMC epithelial cells (Fig. 3.1A).  
Since a previous report indicates that a kinase-inactivating mutation in the KSR1 kinase domain 
reduces KSR1 association with MEK (Yu, et al., 1998), we performed FLAG immunoprecipitation 
on +vector, +KSR1, and +D683A/D700A cell lines and compared MEK binding.  Both KSR1 
proteins were equally competent to co-precipitate endogenous MEK (Fig. 3.1B).  This suggests 
that the D683A/D700A kinase-inactivating mutation in KSR1 had no deleterious effects on MEK 
binding.  To determine if KSR1 was required for TNF-induced cell survival in cultured colon 
epithelial cells, apoptosis was assessed in TNF-treated +vector, +KSR1, and +D683A/D700A cell 
lines by TUNEL assay.  Unlike cells expressing KSR1, those expressing either +vector or 
+D683A/D700A were sensitive to TNF-induced apoptosis (Figs. 3.2A-B).  Previous data from our 
lab indicate that TNF-mediated ERK activation was impaired in cells lacking KSR1 or expressing  
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Figure 3.1: Wild-type KSR1 and kinase-inactive KSR1 associate with MEK.  A) KSR1 protein 
expression was determined by Western blot analysis on whole cell lysates from KSR1-/- mouse 
colon epithelial cells expressing +vector, +KSR1, or +D683A/D700A, or from YAMC cells using 
the indicated antibodies.  B) Co-immunoprecipitation of MEK was determined by Western blot 
analysis on FLAG-immunoprecipitates from +vec, +KSR1, and +D683A/D700A expressing cells.  
Whole cell lysate from +KSR1 cells was used as a control for detecting each protein probed.  
Immunoblots are representatives of at least 3 independent experiments. IP, immunoprecipitation; 
IB, immunoblot. 
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kinase-inactive KSR1 (Yan, et al., 2004).  Therefore, we investigated whether MEK kinase activity 
was required for protection against TNF-induced cell death.  An equal number of cells were pre-
treated with vehicle or the MEK inhibitor U0126 and then treated with TNF.  Cells lacking KSR1 or 
expressing the D683A/D700A mutant KSR1 were sensitive to TNF-induced cell loss, whereas 
+KSR1 cells were not (Fig. 3.2C).   However, the +KSR1 cells were sensitized to TNF-induced 
cell loss following MEK inhibition, whereas U0126 did not potentiate cell loss in cells expressing 
+vector or +D683A/D700A.  Interestingly, treatment of +D683A/D700A cells with U0126 caused 
increased cell loss in the absence of TNF. These data suggest that the protective effect of wild-
type KSR1 is mediated through MEK activation.  In a parallel experiment, U0126 effectively 
blocked TNF-induced ERK phosphorylation, but not p38 MAPK phosphorylation, in +KSR1 cells, 
confirming its specificity for MEK (Fig. 3.2D).  Taken together, these observations demonstrate 
that TNF-induced colon epithelial cell survival requires a functional KSR1 kinase domain, which in 
turn relies on MEK activity. 
 
KSR1 phosphorylates recombinant kinase-inactive MEK1 
The observation that inhibiting MEK activation sensitized +KSR1 cells, but did not 
potentiate cell loss in +D683A/D700A or +vector cells, combined with the prior observation that 
kinase-inactive KSR1 expression attenuates TNF-induced ERK activation (Yan, et al., 2001), 
suggests that KSR1 protein kinase activity may effect MEK activation.  Since MEK activation 
requires phosphorylation on two serine residues in the MEK activation loop (Alessi, et al., 1994; 
Zheng, et al., 1994), we used a phospho-specific antibody to these MEK serine residues 
(S218/S222) to determine the phosphorylation state of KSR1-associated MEK.  FLAG 
immunoprecipitations were performed on serum-starved +vector, +KSR1, and +D683/D700A 
cells.  In cells expressing +KSR1, KSR1-associated MEK was phosphorylated 5-fold over 
+D683A/D700A-associated MEK (Fig. 3.3A), demonstrating that MEK interaction with wild-type 
KSR1 enhances MEK phosphorylation. 
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Figure 3.2: KSR1-mediated protection against TNF-induced apoptosis requires both a 
functional KSR1 kinase domain and MEK kinase activity.  A) TNF-induced apoptosis was 
determined by treating serum-starved +vector, +KSR1, and +D683A/D700A cells with TNF (100 
ng/ml) for 8 hours.  Apoptotic nuclei were labeled using terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL).  B) Apoptotic cells from panel A were quantified and reported 
as the percentage of TUNEL positive cells out of 500 cells.  Solid bars represent the mean for 
each condition and the error bars the SEM.  C) TNF-induced cell loss was determined for cells 
that were pre-treated with vehicle or the MEK inhibitor U0126 (10 µM) for 45 minutes followed by 
TNF (100 ng/ml) for 24 hours.  The total number of adherent cells was quantified and cell loss 
calculated as the percent of the vehicle treated control for each cell line.  Assays were performed 
a minimum of 3 times.  D) The specificity of U0126 was confirmed in +KSR1 cells pretreated with 
vehicle or U0126 (10 µM) for 45 minutes followed by TNF for 15 minutes and assayed for 
phosphorylated ERK.  Protein phosphorylation and total protein were determined by Western blot 
analysis using the indicated antibodies.  Immunoblots are representatives of at least 3 
independent experiments. * = P < 0.05, ** = P < 0.01, *** = P < 0.001	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Figure 3.3: KSR1 phosphorylates MEK1 A) FLAG immunoprecipitation was performed using 
whole cell lysates from KSR1-/- cells expressing +vector, +KSR1, or +D683A/D700A.  MEK 
phosphorylation was determined by Western blot analysis using the indicated antibodies.  
Densitometric analysis was performed on total and phosphorylated co-precipitated MEK protein 
and represented as the ratio of phosphorylated MEK/total MEK.  Solid bars represent the mean 
ratio from 3 independent experiments and error bars represent the SEM.  B) In vitro kinase assay 
using immunoprecipitated FLAG-tagged KSR1 proteins incubated with kinase-inactive rMEK 
K97M.  Total protein and phosphorylated rMEK K97M were determined by Western blot analysis. 
C) In vitro kinase assay performed as before following a 30 minutes pre-incubation with vehicle or 
U0126 (10 mM).  D)  Efficacy of inhibiting an active Raf/MEK/ERK cascade in vitro was assayed 
using recombinant constitutively active Raf-1 (rCA-Raf-1), recombinant MEK1 (rMEK) and 
recombinant ERK (rERK) in the presence of vehicle or U0126 (10 µM). Total and phosphorylated 
proteins were determined by Western blot analysis. IP, immunoprecipitation; IB, immunoblot.	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Based on our observation that MEK phosphorylation was increased when complexed 
with wild-type KSR1, we investigated whether MEK was a KSR1 substrate in an in vitro kinase 
assay.  For these assays we utilized recombinant kinase-inactive MEK1 harboring an amino acid 
substitution at the conserved lysine residue (rMEK K97M) in the MEK kinase subdomain II.  
FLAG immunoprecipitates from each cell line were incubated with rMEK K97M in the presence of 
ATP.  Immunoprecipitates from cells expressing +KSR1, but not +D683A/D700A or +vector were 
able to phosphorylate rMEK K97M, as determined by Western blot analysis (Fig. 3.3B).  Since 
endogenous MEK co-precipitates with KSR1 under non-stringent conditions, we determined if 
endogenous MEK activity was responsible for phosphorylating rMEK K97M.  FLAG 
immunoprecipitates from +KSR1 cells were incubated with either vehicle or U0126 then subjected 
to an in vitro kinase assay using rMEK K97M.  U0126 was unable to block rMEK K97M 
phosphorylation by +KSR1 immunoprecipitates in vitro (Fig. 3.3C).  The efficacy of U0126 in 
these experiments was confirmed by the ability of U0126 to block recombinant wild-type MEK 
(rMEK) phosphorylation of recombinant ERK (rERK) when stimulated by a constitutively active 
recombinant Raf-1 (rCA-Raf-1) (Fig. 3.3D).  These data further indicate that MEK is a substrate 
for KSR1 protein kinase activity.  
 
Recombinant wild-type KSR1 is a functional protein kinase capable of serine 
autophosphorylation. 
Our data utilizing FLAG immunoprecipitation of KSR1 expressed in cell culture for in vitro 
kinase assays suggest that MEK is a substrate of KSR1.  However, these data cannot exclude 
the possibility that KSR1 co-precipitates additional protein kinases.  Ther46efore, to directly assay 
KSR1 kinase activity, we produced recombinant wild-type KSR1 (rKSR1) or recombinant kinase-
inactive KSR1 (rD683A/D700A) in E. coli.  We first examined the ability of rKSR1 proteins to co-
precipitate with rMEK K97M.  Consistent with our cell culture data, both rKSR1 and 
rD683A/D700A were equally competent in MEK binding (Fig. 3.4A).  To determine if rKSR1 is 
capable of autophosphorylation, we performed in vitro kinase assays using [γ-32P]ATP with  
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Figure 3.4: Recombinant KSR1 undergoes serine autophosphorylation.  A) rKSR1 and 
rD683A/D700A proteins were incubated with rMEK K97M for 2 hours an then immunoprecipitated 
with aFLAG antibody. MEK co-precipitation was determined by Western blot analysis using the 
indicated antibodies.  B) KSR1 autophosphorylation was assayed using in vitro kinase assays in 
which rKSR1 or rD683A/D700A were incubated in the presence of [γ-32P]ATP at 30o C for 30 
minutes.  rKSR1 and rD683A/D700A samples were then separated by SDS-PAGE and 32P 
incorporation was determined by autoradiography and total KSR1 protein detected by Western 
blot analysis.  C) Phosphoamino acid analysis was conducted on 32P-rKSR1 following an in vitro 
kinase assay.  Phosphorylated amino acids were determined by autoradiography.  Dashed lines 
indicate the migration of phosphoamino acid standards.  D) In vitro kinase assay with rKSR1 and 
rD683A/D700A in the presence of [γ-32P]ATP with vehicle or C8-ceramide (3 µM).  KSR1 
autophosphorylation was determined as before.  Total KSR1 protein was detected by Western 
blot analysis.  Autoradiography and immunoblots are representatives of 3 independent 
experiments. IP, immunoprecipitation; IB, immunoblot. 	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Figure 3.5: rKSR1 autophosphorylation is not enhanced by ceramide in vitro.  In vitro 
kinase assay using recombinant KSR1 (rKSR1) in the presence of vehicle or 3mM C2-, C8-, or 
C16-ceramide and [g-32P]ATP.  Phosphorylated KSR1 was detected by autoradiography and total 
KSR1 protein was determined by Western blot analysis.  Immunoblot and autoradiography is a 
representative of 3 independent experiments. IB, immunoblot. 	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bacterially derived KSR1 proteins.  We found that rKSR1 but not rD683A/D700A incorporated 32P, 
indicating that rKSR1 undergoes autophosphorylation (Fig. 3.4B).  To determine which amino 
acid residue(s) were autophosphorylated we performed phosphoamino acid analysis on rKSR1 
following the [γ-32P]ATP in vitro kinase assay.  We found that rKSR1 autophosphorylation 
occurred exclusively on serine residue(s) (Fig. 3.4C).  Further analysis using 2D tryptic 
phosphopeptide mapping indicated that KSR1 autophosphorylation likely occurs on a single or 
limited number of serine residues (data not shown).  
Since previous studies from our lab and others describe KSR1 as a ceramide-activated 
protein kinase, we determined if rKSR1 autophosphorylation was modulated by ceramide (Yan, et 
al., 2001; Zhang, et al., 1997).  In vitro kinase assays were performed using rKSR1 or 
rD683A/D700A in the presence or absence of ceramide.  The addition of C8-ceramide did not 
enhance rKSR1 autophosphorylation in this assay (Fig. 3.4D).   Since ceramide bioactivity varies 
depending on the structure and length of the hydrocarbon chain (Siskind, et al., 2000), we tested 
the effect of various ceramide analogs in augmenting rKSR1 kinase activity. The addition of C2-, 
C8-, or C16-ceramide to the kinase reaction had no effect on rKSR1 autophosphorylation (Fig. 
3.5).   Collectively, these data demonstrate that rKSR1 is a functional protein kinase that 
undergoes serine autophosphorylation likely on a limited number of serine(s) in a ceramide-
independent manner.   
 
KSR1 phosphorylates Myelin basic protein (MBP) in vitro 
MBP is commonly used as a generic substrate to assay for protein kinase activity in vitro 
(Erickson, et al., 1990; Kishimoto, et al., 1985; Shoji, et al., 1987).  To determine if rKSR1 is able 
to phosphorylate MBP, we performed in vitro kinase assays with rKSR1 and rD683A/D700A.  
Similar to recombinant Raf-1 (rRaf-1) rKSR1, but not rD683A/D700A, was able to phosphorylate 
MBP (Fig. 3.6A).  We also tested if the KSR1 kinase domain (rKSR1ΔN521) was sufficient to 
phosphorylate MBP.  Consistent with previous reports, rKSR1 kinase activity requires full length 
KSR1 (Fig. 3.6A) (Xing, et al., 2000).  As a positive control for MBP phosphorylation, we  
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Figure 3.6: Recombinant KSR1 phosphorylates Myelin basic protein (MBP).   A) 
Recombinant rKSR1, rD683A/D700A, rKSR1DN521, rRaf-1, or rRaf-1 K375M proteins, or lysate 
from EGF-treated cells (EGF tx lysate) were incubated with MBP in an in vitro kinase assay.  
Solid bars are the average relative MBP phosphorylation compared to MBP alone and error bars 
represent the SEM from 3 independent experiments.  B) In vitro MBP kinase assay performed as 
before with rKSR1 or rD683A/D700A incubated with vehicle, C2-, C8-, or C16-ceramide (3 µM).  
MBP phosphorylation was determined as before.  Solid bars are the average relative MBP 
phosphorylation compared to MBP alone and error bars represent the SEM from 3 independent 
experiments.  Statistical analysis was performed using a one-way ANOVA with Dunnettʼs post-
test.  *** = P < 0.001  	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incubated MBP with whole cell lysate from EGF treated YAMC cells (EGF tx) (Fig. 3.6A).  These 
findings indicate that rKSR1 can phosphorylate MBP as a generic substrate. 
We next tested if rKSR1 phosphorylation of MBP was augmented by ceramide.  rKSR1 
and rD683A/D700A were incubated with MBP in the presence of C2, C8, or C16-ceramide.  
Phosphorylation of MBP by rKSR1 was not potentiated by any of the ceramide analogs 
suggesting that ceramide does not regulate rKSR1 kinase activity in vitro (Fig. 3.6B).  The activity 
of ceramide was confirmed by treating YAMC cells with each ceramide analog and ERK 
activation was detected by Western blot analysis (data not shown).  Together, these observations 
indicate that only full-length wild-type rKSR1 can directly phosphorylate MBP as a generic 
substrate and that ceramide does not appear to regulate rKSR1 kinase activity. 
 
Recombinant KSR1 phosphorylates recombinant kinase-inactive MEK1. 
Since +KSR1 cells showed enhanced endogenous MEK phosphorylation and FLAG 
immunoprecipitation from these cells phosphorylated rMEK K97M (Figs. 3.3A-B), we assessed 
whether MEK was a substrate for recombinant KSR1.  In vitro kinase assays were performed 
incubating rMEK K97M with rKSR1, rD683A/D700A, or rRaf-1 as a positive control.  Similar to 
rRaf-1, rKSR1 phosphorylated rMEK K97M (Fig. 3.7A).  Furthermore, no kinase activity was 
detected in a second kinase-inactive KSR1 mutant where the putative ATP-binding arginine was 
substituted with methionine (rR589M) (Fig. 3.7A).  Since previous data indicate that mutations in 
the D. melanogaster KSR1 CA1 domain reduced KSR1 function (Therrien, et al., 1995), we 
generated a recombinant amino-terminal deletion of KSR1 (rKSR1ΔCA1).  rKSR1ΔCA1 was 
unable to phosphorylate rMEK K97M, suggesting that the CA1 domain may be required 
structurally or facilitates KSR1 enzymatic activity through an unknown mechanism (Fig. 3.7A).  
Taken together, these data demonstrate that rKSR1 can phosphorylate rMEK K97M as a 
substrate consistent with the observations for KSR1 immunoprecipitated from colon epithelial 
cells.    
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Figure 3.7: Recombinant KSR1 phosphorylates rMEK K97M.  A) Phosphorylation of rMEK 
K97M was assayed using in vitro kinase assays by incubating rMEK K97M with rKSR1, 
rD683A/D700A, rR589M, rKSR1DCA1, or rRaf-1.  Phosphorylated rMEK K97M was assayed 
by Western blot analysis using the indicated antibodies.  B) rKSR1-stimulated recombinant 
ERK (rERK) phosphorylation was determined using in vitro kinase assays in which rKSR1 or 
rD683A/D700A was incubated with rMEK in the presence rERK.  Protein phosphorylation and 
total protein were determined by Western blot analysis using indicated antibodies.  
Immunoblots are representative of 3 independent experiments.	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Figure 3.8: Immunoprecipitated KSR1 promotes rMEK activation A) FLAG-tagged Raf-1 was 
immunoprecipitated from increasing quantities of total protein (400-800 µg) from whole cell lysate, 
gel-loaded along with increasing amount of purified recombinant CA-Raf-1 (0.01-0.32 µg), and 
separated by SDS-PAGE.  Densitometric measurements were obtained from Western blot 
analysis using an aRaf-1 antibody.  Linear regression using rCA-Raf-1 as the protein standard 
determined the amount of immunoprecipitated FLAG-tagged Raf-1.  Immunoblot is a 
representative of 3 different experiments.  B) FLAG-tagged KSR1 was immunoprecipitated from 
increasing quantities of total protein (400-1000 µg) from whole cell lysate, gel-loaded along with 
increasing amount of purified recombinant FLAG-tagged bacterial alkaline phosphatase (BAP) 
(0.01-0.32 µg), and separated by SDS-PAGE.  Densitometric measurements were obtained from 
Western blot analysis using an αFLAG antibody.  Linear regression using rFLAG-BAP as the 
protein standard determined the amount of immunoprecipitated FLAG-tagged KSR1 protein. C) 
The ability of mammalian FLAG-KSR1, FLAG-D683A/D700A, or FLAG-Raf-1 to promote rMEK 
kinase activity towards ERK was determined by immunoprecipitating 1 pmol of each FLAG-
tagged protein and performing an in vitro kinase assay with recombinant kinase-dead ERK (rERK 
K52R) in the presence or absence of rMEK.  Total and phospho-proteins were determined by 
Western blot analysis as indicated.  Immunoblots are representatives of 3 independent 
experiments. IP, immunoprecipitation; IB, immunoblot.	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While rKSR can phosphorylate rMEK K97M, utilizing kinase-inactive MEK does not allow 
for assaying rKSR-mediated MEK activation.  Therefore, we determined if rKSR1 is able to 
phosphorylate unactive recombinant wild-type MEK (rMEK).  In vitro kinase assays were 
performed incubating unactive rMEK with rKSR1, rD683A/D700A, or rRaf-1.  To determine if 
rKSR1 phosphorylation of rMEK is sufficient to activate rMEK, we performed an in vitro kinase 
assay using unactive recombinant wild-type ERK (rERK) as the rMEK substrate.  While rMEK 
phosphorylation by rKSR1 was readily detected, it was insufficient to induce rERK 
phosphorylation (Fig. 3.7B).  We then investigated whether KSR1, D683A/D700A, or Raf-1 
proteins immunoprecipitated from mammalian cells promoted rMEK kinase activity towards 
recombinant kinase-dead ERK (rERK K52R). We first determined the quantity of 
immunoprecipitated proteins to ensure equimolar amounts of KSR1 and Raf-1 proteins to be used 
in the kinase assay (Fig. 3.8A-B).  We then performed in vitro kinase assays incubating rERK 
K52R with immunoprecipitated FLAG-KSR1 (1 pmol), FLAG-D683A/D700A (1 pmol), FLAG-Raf-1 
(1 pmol), or FLAG-Raf-1 (1pmol) from EGF treated cells as a positive control in the presence or 
absence of unactive rMEK.  We found that FLAG-KSR1 and FLAG-Raf-1, but not FLAG-
D683A/D700A, immunoprecipitated from mammalian cells promoted rERK K52R phosphorylation 
by rMEK (Fig. 3.8C).  As a positive control for MEK activation, we performed the same kinase 
assay using rMEK and ERK K52R incubated with FLAG-Raf-1 immunoprecipitated from EGF 
treated cells.  Collectively, these data suggest that while MEK is a KSR1 substrate in vitro, 
activation of rMEK requires KSR1 isolated from intact mammalian cells.    
 
 
Discussion 
Our findings indicate that KSR1 is a functional protein kinase that, along with MEK1 
protein kinase activity, is required for protection against TNF-induced cell death.  The observation 
that MEK associated with wild-type KSR1 has increased phosphorylation, together with our in 
vitro kinase assays using recombinant proteins, suggests that KSR1 is capable of direct 
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phosphorylation of MEK.  With the prevailing controversy surrounding KSR1 as a functional 
protein kinase, the results presented here showing that recombinant KSR1 is serine 
autophosphorylated and is capable of phosphorylating MBP, solidifies KSR1 as a functional 
protein kinase.  Furthermore, we have found that both recombinant KSR1 and KSR1 
immunoprecipitated from colon epithelial cells are able to phosphorylate recombinant kinase-
inactive MEK1.  Interestingly, while phosphorylation of rMEK by rKSR1 occurs within the MEK 
activation loop, only mammalian KSR1 was able to promote rMEK activation.  Collectively, the 
data presented here support a role for KSR1 as a catalytically active protein kinase that functions 
to promote cell survival in the presence of TNF.  This finding has implications for chronic 
inflammatory diseases, such as inflammatory bowel disease (IBD), in which the cytotoxic effect of 
TNF contributes to epithelial cell loss and epithelial barrier dysfunction.  
Activation of the ERK cascade is a key component for cell survival in a number of cell 
types (Erhardt, et al., 1999; Le Gall, et al., 2000; McKay, et al., 2007; Ripple, et al., 2005; 
Shimamura, et al., 2000).  While the ability of KSR1 to scaffold and sensitize the ERK pathway is 
well-established (Fusello, et al., 2006; Lin, et al., 2009; Xing, et al., 2000), the catalytic 
contribution of KSR1 has remained inconclusive.  We found that colon epithelial cells lacking 
KSR1, or stably expressing a kinase-inactive KSR1, are sensitive to TNF-induced apoptosis (Fig. 
3.2A).  Interestingly, inhibition of MEK protein kinase activity sensitized +KSR1 cells to TNF-
induced cell loss whereas +vector and +D683A/D700A cells had no potentiation in cell loss (Fig. 
3.2C).  This suggests that the protective role of KSR1 kinase activity requires MEK kinase 
activity.  The importance of MEK1 is established from early development, as MEK1-/- mice are 
embryonic lethal (Giroux, et al., 1999).  In fact, a study utilizing an inducible tissue-specific 
deletion of MEK1 in the epidermis causes keratinocyte apoptosis (Scholl, et al., 2007).  It is 
conceivable that wild-type KSR1 augments MEK kinase activity through protein-protein 
interactions independent of catalytic function in a manner similar to Raf-1 (Michaud, et al., 1997; 
Rajakulendran, et al., 2009).  This seems unlikely given that +D683A/D700A-binding affinity for 
MEK is equivalent to wild-type KSR1, yet +D683A/D700A cells are just as sensitive to TNF-
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induced apoptosis as cells lacking KSR1 (Fig. 3.2C).  Alternatively, expression of wild-type KSR1 
may induce a different protein expression profile compared to the protein profiles of +vector and 
+D683A/D700A cells such that MEK activity is required.  
Previous studies using immunoprecipitated KSR1 from cultured cells reveal that KSR1 
autophosphorylates and phosphorylates Raf-1 in response to ceramide (Yan, et al., 2004; Zhang, 
et al., 1997).  While our results indicate that recombinant KSR1 autophosphorylates exclusively 
on serine, consistent with previous results (Liu, et al., 1994), ceramide was not required for 
recombinant KSR1 protein kinase activity in vitro (Figs. 3.4D & 3.5).  We cannot rule out a role for 
ceramide in activating endogenous KSR1.  The requirement for ceramide in KSR1 activation 
observed by others may provide insight into KSR1 regulation.  For instance, ceramide could 
function to relieve a negative regulatory mechanism mediated by other associated proteins such 
as the 14-3-3 family, similar to Raf-1, through activation of PP2A (Cacace, et al., 1999; 
Dobrowsky, et al., 1992; Hartsough, et al., 2002; McPherson, et al., 1999; Müller, et al., 2001; 
Volle, et al., 1999; Xing, et al., 1997).  It is attractive to speculate that since recombinant KSR1 
does not require activation by ceramide, KSR1 must adopt an active conformation or be 
allosterically modulated through an intramolecular interaction.  Regulation of endogenous KSR1 
might occur by sequestering these interacting regions within the molecule.  In fact, the original 
mutagenesis screen in D. melanogaster detailed a weak loss of function allele that mapped to a 
double amino acid substitution within the KSR1 CA1 domain.  This domain is a highly conserved 
domain unique to the KSR1 family and is important for interactions with B-Raf (McKay, et al., 
2009).  Interestingly, recombinant KSR1 with an N-terminal truncation of this domain 
(rKSR1ΔCA1) did not function as an active kinase (Fig. 3.7A).  Additionally, a construct containing 
only the KSR1 kinase domain (rKSR1ΔN521) was unable to phosphorylate MBP (Fig. 3.6A).  This 
finding is consistent with a report that the N-terminus is required for KSR1 protein kinase activity 
(Xing, et al., 2000).  This is unlike Raf1 where expression of the kinase domain alone results in a 
constitutively active enzyme (Boerth, et al., 1994; Hecht, et al., 1996).   
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The finding that MEK1 is a KSR1 substrate raises new questions about the potential 
mechanisms that modulate the ERK pathway.  The data presented here show that rKSR1 can 
phosphorylate rMEK1 on at least one serine residue within the MEK1 activation loop (Figs. 3.3B 
& 3.7A).  These serine residues in the MEK activation loop are reported to be both necessary and 
sufficient for phosphorylation of ERK (Alessi, et al., 1994; Zheng, et al., 1994).  Interestingly, 
while rKSR1 phosphorylation of rMEK was insufficient to stimulate phosphorylation of rERK2 (Fig. 
3.7B), KSR1 immunoprecipitated from mammalian cells did promote rMEK activation (Fig. 3.8C).  
It is conceivable that KSR1 expressed in mammalian cells may possess post-translational 
modifications that may promote more efficient activation of rMEK.  We cannot rule out the 
possibility that immunoprecipitated wild-type KSR1 promotes rMEK activation through an 
allosteric mechanism in a manner similar to KSR1-stimulated Raf-1 activation (Rajakulendran, et 
al., 2009).  In addition, previous observations with MEK kinase-1 (MEKK1) also indicate a level of 
complexity in MEK activation.  While MEKK1 transfected into 293 cells readily phosphorylated 
MEK1 and MEK2 at these serine residues, it did not result in phosphorylation of ERK2 (Xu, et al., 
1995).  Our data presented here, combined with previous data for MEKK1, suggests that MEK 
activation is regulated, at least in part, by additional factors that likely vary with the type of 
stimulus or expression system.  Nonetheless, the in vivo contribution of KSR1 kinase activity 
towards MEK may function to sensitize MEK activation by Raf-1, or regulate the spatiotemporal 
phosphorylation state of MEK.  In fact, the spatiotemporal control of ERK activation is able to alter 
the physiological responses downstream of both TNF receptor-1 and staphylococcal enterotoxin 
E-mediated T cell activation (Kaiser, et al., 1999; Lin, et al., 2009).  Thus, KSR1 kinase activity 
towards MEK may function to make MEK activation by Raf or other MEK kinases more efficient 
and/or lower the threshold for activation of the ERK pathway. 
For over a decade, KSR1 has been appreciated as a scaffold of the ERK pathway that 
coordinates pathway activation, yet the enzymatic contributions of KSR1 have remained 
controversial (Denouel-Galy, et al., 1998; Michaud, et al., 1997; Sugimoto, et al., 1998; Therrien, 
et al., 1996; Yu, et al., 1998).  The data presented here demonstrate that KSR1 contains intrinsic 
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protein kinase activity in vitro and suggests a mechanism by which KSR1 can sensitize the ERK 
signaling cassette through direct phosphorylation of MEK1.  KSR1 and other protein kinases have 
been classified as pseudokinases based on variation in conserved amino acid residue(s) within 
the kinase domain (reviewed in (Boudeau, et al., 2006)).  Even so, the maintenance of a highly 
conserved protein kinase domain throughout evolution, and the demonstration of protein kinase 
activity from other unique protein kinases (Abe, et al., 2001; Xu, et al., 2000), imparts significance 
to these proteins and their potential enzymatic function.  Our observation that the catalytic activity 
of KSR1 protects colonic epithelial cells from TNF-induced apoptosis provides a potential 
mechanism by which the intestinal epithelial barrier can be maintained in the presence of 
elevated levels of TNF.  For patients suffering from IBD, anti-TNF therapy is beneficial and able to 
induce remission.  Yet, the long-term side effects, and concomitant immunosuppressive therapy, 
highlight the need for novel strategies that reduce inflammation by promoting epithelial cell 
survival within the inflammatory microenvironment  (reviewed in (Rutgeerts, et al., 2006)).  
Therefore, understanding the precise mechanisms that modulate the ERK pathway downstream 
of TNF could lead to new therapeutic targets for patients afflicted with chronic inflammatory 
diseases. 
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CHAPTER IV 
 
KSR1 PROTECTS AGAINST INTERLEUKIN-10 DEFICIENCY-INDUCED COLITIS IN MICE BY 
SUPPRESSING T LYMPHOCYTE INTERFERON-γ PRODUCTION 
 
Introduction 
Pathogen defense mechanisms, such as innate and adaptive immunological responses, 
have greatly contributed to the success of vertebrate evolution. While acute inflammatory 
responses are beneficial to the host, chronic inflammation can be deleterious.  Thus, identification 
of the molecules involved in regulating these responses is critical for understanding the 
mechanisms that can contribute to immunological disorders.  For patients suffering from IBD, 
dysregulated immune responses result in sustained immune cell activation and elevated cytokine 
production, which can lead to an increased risk for developing colon cancer over their lifetime 
(Balkwill, et al., 2001; Itzkowitz, et al., 2004).  Therefore, it is imperative to develop strategies and 
identify novel targets that modulate immune responses to complement current therapeutic options 
for IBD patients.    
Much of our current understanding of the molecular mechanisms involved in IBD has 
come from knockout, transgenic, and chemically-induced mouse models.  Although mouse 
models of IBD do not fully recapitulate the human disease, interleukin-10 deficient (Il10-/-) mice 
display similar characteristics to that of human Crohnʼs disease (Rennick, et al., 1995; Scheinin, 
et al., 2003).  Since the anti-inflammatory effects of IL-10 are required to regulate Th1 cytokine 
production and promote immune homeostasis (Fiorentino, et al., 1989; Maynard, et al., 2007), 
loss of IL-10 in mice results in spontaneous enterocolitis driven by an aberrant immunological 
response to enteric antigens (Kühn, et al., 1993; Sellon, et al., 1998). 
KSR1 functions as a kinase or molecular scaffold of the Raf/MEK/ERK signaling module 
to regulate proliferation, apoptosis or function in a cell/tissue context-dependent manor (Michaud, 
et al., 1997; Zafrullah, et al., 2009; Zhang, et al., 1997).  For example, KSR1 is required for colon 
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epithelial cell survival downstream of TNF signaling both in vitro and in vivo (Yan, et al., 2001; 
Yan, et al., 2004).  Given that pro-inflammatory cytokines, including TNF, are elevated in Il10-/- 
mice, we hypothesized that loss of KSR1 in Il10-/- mice would exacerbate colitis.  Therefore, we 
crossed KSR1-/- mice with Il10-/- mice to generate KSR1-/-Il10-/- mice and examined the role of 
KSR1 as a protective mediator during chronic inflammation. 
In the present study, we found that KSR1-/-Il10-/- mice developed an early onset form of 
severe colitis resulting from loss of KSR1 expression in hematopoietic lineages.  Specifically, 
KSR1 deficient T cells produced more IFN-γ and had a greater propensity to polarize along the 
Th1 axis in vitro.  The data presented here, along with recent reports, reveal an emerging role for 
KSR1 in immune function. 
 
Results 
 
KSR1-/-Il10-/- mice develop accelerated spontaneous colitis 
Although KSR1 inhibits epithelial cell apoptosis downstream of TNF signaling (Yan, et al., 
2004), the role of KSR1 during chronic inflammation has not been examined.  Since Il10-/- mice on 
the BALB/c (WT) strain under SPF conditions develop spontaneous colitis between 12-16 weeks 
of age, we examined the effect of KSR1 deficiency on colitis in Il10-/- mice. The clinical onset of 
disease was assessed for each group of mice by examination of fecal occult blood and 
monitoring whole body weight from 3 to 10 weeks.  KSR1-/-Il10-/- mice frequently suffered from 
chronic diarrhea and failed to thrive beginning at 5 weeks of age (Fig. 4.1A).  By colonoscopic 
examination, the mucosa of 10-week old KSR1-/-Il10-/- mice appeared thickened with loss of 
normal vascular pattern compared to the colonic mucosa of WT, KSR1-/-, and Il10-/- mice (Fig. 
4.1B).  Since colon weight per unit length is often indicative of inflammation, colon length-to-
weight (l/w) ratio was quantified for each group.  KSR1-/-Il10-/- mice had an average l/w ratio of 
15.03 ± 1.5 whereas WT, KSR1-/-, and Il10-/- mice had ratios of 44.36 ± 2.96, 41.64 ± 3.24, and  
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Figure 4.1: KSR1-/-Il10-/- mice develop accelerated spontaneous colitis.  A) WT, KSR1-/-, Il10-
/-, and KSR1-/-Il10-/- mice were weighed weekly from 3 weeks of age to 10 weeks.  Plotted data 
are the mean weight for each group (n ≥ 5).  Error bars represent the SEM.  B) Mouse 
colonoscopic images taken on 10-week old mice.  C) Colons were removed from 10-week old 
mice flushed, weighed, and measured from the cecum to anus.  Solid bars represent the mean (n 
≥ 3) of the length/weight ratios. Error bars represent the SEM. D) Paraffin embedded colon 
sections from 10-week old mice stained with Hematoxylin and Eosin (H&E).  Images were taken 
at 20X magnification (scale bars, 50 µm). E) H&E stained 10-week old mouse colon sections 
were scored by a pathologist blinded to the genotype.  Solid bars represent the mean injury and 
inflammation score for each group (n ≥ 6) and error bars are the SEM. F) KSR1-/-Il10-/- mice were 
sacrificed at each time point indicated and scored for inflammation and injury as before. * P < 
0.05, ** P < 0.01, *** P < 0.001 
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Figure 4.2: KSR1-/-Il10-/- mice have increased colon epithelial barrier permeability and 
increased epithelial cell turnover.  A) Colonic barrier permeability was assayed by the 
administration of fluorescein isothiocyanate (FITC)-dextran enemas in 10-week old mice.  Mouse 
serum was collected after 1 hour and FITC in peripheral blood serum was determined using a 
fluorescence microplate reader.  Solid bars represent the mean and error bars represent the SEM 
from three independent experiments.  B) Paraffin embedded colon sections from WT, KSR1-/-, 
Il10-/-, and KSR1-/-Il10-/- (DKO) mice were labeled using terminal deoxynucleotidyl transferase 
dUTP nick end labeling (TUNEL).  Black arrows indicate TUNEL positive cells.  All images were 
taken at 20X magnification (scale bars, 50 µm).  C) Colon epithelial cell apoptosis was quantified 
by counting the number of TUNEL and in situ oligo ligation (ISOL) labeled epithelial cells per 100 
crypts.   Bars represent the mean and error bars the SEM (n ≥ 3) from three independent 
experiments.  D) Immunohistochemical staining performed on paraffin embedded colon sections 
from WT, KSR1-/-, Il10-/-, and DKO mice using an anti-Ki67 antibody.  Images were photographed 
at 20X magnification (scale bars, 50 µm). E) Epithelial cell proliferation was quantified by counting 
the number of Ki67 or phospho-histone H3 positive cells per 100 crypts, as indicated. Solid bars 
represent the mean and error bars represent the SEM (n ≥ 3) from three independent 
experiments.  *** P < 0.001 
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38.19 ± 2.34 respectively (Fig. 4.1C).  Paraffin-embedded colon sections from 10-week old mice 
were stained with Hematoxylin and Eosin (H&E) and a blinded pathologist scored each section for 
inflammation and injury. 10-week old KSR1-/-Il10-/- mice suffer from severe colitis (score of 9.83 ± 
0.6) (Figs. 4.1D-E).  Barrier permeability was assed by administering FITC-dextran enemas to 10-
week old mice, peripheral blood serum collected one hour later, and quantified for the presence of 
FITC. KSR1-/-Il10-/- mice had increased barrier permeability, possibly due to the increased 
epithelial cell turnover as determined by apoptotic and proliferative markers (Fig. 4.2).  We then 
evaluated the developmental time course of colitis and found at 4 weeks of age, KSR1-/-Il10-/- mice 
already have histological signs of disease (Fig. 4.1F).  These data indicate that loss of KSR1 in 
Il10-/- mice results in accelerated and severe spontaneous colitis with retarded growth similar to 
findings in children with Crohnʼs disease (Heuschkel, et al., 2008). 
  
Expression of KSR1 in hematopoietic lineages is protective against colitis 
The KSR1-/- and Il10-/- knockout mice in this study were engineered as global deletions.  
Since the disease that develops in Il10-/- mice is attributed to immune hypersensitivity to enteric 
microflora (Kühn, et al., 1993; Sellon, et al., 1998), we investigated whether KSR1 expression in 
hematopoietic lineages mediated protection from disease in Il10-/- mice.  To test this, we 
performed bone marrow transplantation on irradiated 4-week old WT or KSR1-/-Il10-/- recipient 
mice.  Following transplant, mice were sacrificed at 10 weeks of age and the inflammation and 
injury in the colon was scored as before.  Irradiated KSR1-/-Il10-/- mice reconstituted with WT bone 
marrow (BM) developed mild colitis scores (2.8 ± 1.12) while reconstitution using KSR1-/-Il10-/- 
bone marrow resulted in severe colitis as expected (11 ± 1) (Figs. 4.3A and 4.3B panels 1 & 4).  
Interestingly, restoring IL-10 to hematopoietic lineages in KSR1-/-Il10-/- mice did not ameliorate 
colitis (8.1 ± 1.72) (Figs. 4.3A and 4.3B panel 3).  However, restoring KSR1 to hematopoietic cells 
in KSR1-/-Il10-/- mice (5.5 ± 1.25) attenuated the disease (Figs. 4.3A and 4.3B panel 2).  
Interestingly, reconstitution of WT mice with Il10-/- BM was insufficient to cause disease, while  
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Figure 4.3: KSR1 in hematopoietic lineages suppresses colitis in Il10-/- mice.   A) 4-week old 
WT and KSR1-/-Il10-/- (DKO) recipient mice were irradiated with 9 Gy 137Cesium.  Bone marrow 
transplants using the indicated donor mice were performed and mice were sacrificed at 10-weeks 
of age.  Each individual colonic injury and inflammation score is plotted with a solid line indicating 
the mean score for each group (n ≥ 3) pooled from three independent experiments and error bars 
are the SEM.  B) Representative H&E stained paraffin embedded colon sections from recipient 
DKO mice transplanted with WT (1), Il10-/- (2), KSR-/- (3), or KSR1-/-Il10-/- (4) bone marrow as 
indicated. *  P < 0.05, ** P < 0.01	  
	  
67 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: KSR1 is not required for stimulated T cell proliferation or leukocyte 
differentiation.  A) Splenocytes isolated from WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice were 
plated in 96-well plates containing plate-bound anti-CD3/anti-CD28 for 72 hours at 37° C then 
pulsed for 18 hours with 1 µCi/well [3H]thymidine.  Proliferation was recorded as [3H]thymidine 
incorporation of stimulated wells relative to unstimulated.  Solid line is the mean (n = 5) for each 
group and error bars the SEM from three independent experiments.  B) Peripheral blood 
leukocyte populations were analyzed using an automated HemaVet counter and recorded as 
percent leukocytes.  Solid bars represent the mean and error bars represent the SEM from 3 
independent experiments (n ≥ 3). 	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KSR1-/-Il10-/- BM injected into irradiated WT mice was sufficient to drive colitis (5.25 ± 0.84) (Fig. 
4.3A).  While hematopoietic cells require KSR1 to suppress colitis in KSR1-/-Il10-/- mice, KSR1 
was not required for leukocyte differentiation or stimulated T cell proliferation in vitro (Figs. 4.4A-
B).  Taken together, our data suggest that KSR1 expression in hematopoietic lineages plays a 
significant role in suppressing colitis in Il10-/- mice. 
 
Stimulated CD4+TCRβ+ splenocytes from KSR1-/- and KSR1-/-Il10-/- mice have increased IFN-γ 
production 
Pro-inflammatory cytokines including TNF, IFN-γ, and IL-17 are increased in the intestinal 
mucosa of Crohnʼs disease patients and in mouse models of IBD (Breese, et al., 1993; Cua, et 
al., 2003; Langrish, et al., 2005; MacDonald, et al., 1990; Murphy, et al., 2003).  Examination of 
Th1 and Th17 gene expression in the colonic mucosa of WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- 
mice revealed that IFN-γ and IL-17A transcripts were increased KSR1 deficient mice (Fig. 4.5).  
Splenocytes were isolated and stimulated with phorbol 12-myristate 13-acetate (PMA)/ionomycin 
and intracellular IFN-γ and IL-17A production examined by flow cytometry.  CD4+TCRβ + 
lymphocytes isolated from KSR1-/- and KSR1-/-Il10-/- mice had increased intracellular IFN-γ 
(12.80% ± 1.16% and 13.5% ± 2.87% respectively) compared Il10-/- mice (6.83% ± 2.03%) and 
WT mice (7.02% ± 1.58%) (Fig. 4.6).  Interestingly, only splenocytes isolated from KSR1-/-Il10-/- 
mice had elevated IL-17A compared to WT mice (1.82% ± 0.4% vs. 0.32% ± 0.03%) (Fig. 4.6).  
Thus, KSR1 expression modulates IFN-γ production in CD4+TCRβ + T lymphocytes. 
 
Th1 polarization is enhanced while Th17 polarization is impaired in KSR1 deficient CD4+TCRβ+ T 
cells in vitro 
IL-17A production by Th17 effector cells has been implicated in the pathogenesis of 
diseases including rheumatoid arthritis, multiple sclerosis, and Crohnʼs disease (Kebir, et al., 
2007; Koenders, et al., 2006; Yagi, et al., 2007).  Our previous observations that IFN-γ and IL-17A 
transcripts were increased in mice lacking KSR1 raised the possibility that KSR1 plays a role in  
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Figure 4.5: IFN-γ  and IL-17A gene expression is increased in the colon of KSR1-/- and 
KSR1-/-Il10-/- mice.  Total RNA was isolated from homogenized whole colon tissue from 10 week-
old WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice. Th1 and Th17 cytokine transcript levels were 
analyzed by quantitative real-time PCR for TNF, IFN-γ, IL-1β, IL-17A, IL-21, and IL-22.  Solid bars 
represent the mean (n ≥ 6) for each genotype and error bars represent the SEM pooled from 
three independent experiments. * P < 0.05, ** P < 0.01, *** P < 0.001 
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Figure 4.6: Stimulated splenocytes from KSR1-/- and KSR1-/-Il10-/- mice have increased IFN-
γ  production.  Splenocytes isolated from WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice were cultured 
for 5 hours in the presence of the protein transport inhibitor GolgiPlug and treated with or without 
PMA/Ionomycin.  Lymphocytes were stained for CD4 and TCRb cell surface markers followed by 
intracellular IFN-γ and IL-17A.  Samples were analyzed by flow cytometry gated on lymphocyte 
geometry and CD4+TCRb+ staining.  A) Flow cytometry dot plots of unstimulated and stimulated 
WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- T cells stained for intracellular IFN-γ and IL-17A.  B) 
Intracellular cytokine staining was quantified and solid bars represent the mean (n ≥ 4) for each 
cultured T cell population pooled from three independent experiments and error bars are the 
SEM.  ** P < 0.01 	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Figure 4.7: In vitro Th17 polarization is impaired in KSR1-/- T cells.  Splenocytes isolated from 
WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice were cultured under Th17 polarizing conditions as 
described.  Lymphocytes were stained for cell surface CD4 and TCRβ and intracellular IFN-γ and 
IL-17A.  Samples were analyzed by flow cytometry gated on lymphocyte geometry and 
CD4+TCRβ+ cell surface staining.  A) Flow cytometry dot plots of unstimulated and stimulated T 
cells cultured under Th17 polarizing conditions. B) Intracellular cytokine staining on Th17 
polarized cells was quantified and reported as the percent CD4+TCRβ+ cells staining positive for 
IL-17A or IFN-γ.  Bar graphs represent the mean (n ≥ 4) for each cultured T cell population pooled 
from two independent experiments.  Error bars are the SEM.   
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Figure 4.8: In vitro Th1 polarization is increased in KSR1-/- T cells.  Splenocytes isolated from 
WT, KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice were cultured under Th1 polarizing conditions as 
described.  Lymphocytes were stained for cell surface CD4 and TCRβ and intracellular IFN-γ and 
IL-17A.  Samples were analyzed by flow cytometry gated on lymphocyte geometry and 
CD4+TCRβ+ cell surface staining. A) Flow cytometry dot plots of unstimulated and stimulated T 
cells cultured under Th1 polarizing conditions. B) Intracellular cytokine staining on Th1 polarized 
cells was quantified and reported as the percent CD4+TCRβ+ cells staining positive for IL-17A or 
IFN-γ.  Bar graphs represent the mean (n ≥ 4) for each cultured T cell population pooled from two 
independent experiments.  Error bars are the SEM.    * P < 0.05, ** P < 0.01, *** P < 0.001 
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T cell development along the Th1/Th17 axis.  To test this, we isolated splenocytes from WT, 
KSR1-/-, Il10-/-, and KSR1-/-Il10-/- mice and cultured them under Th1 or Th17 polarizing conditions.  
We then stimulated with PMA/ionomycin for 5 hours in the presence of GolgiPlug and measured 
intracellular IL-17A and IFN-γ production by flow cytometry.  We found that under Th17 polarizing 
conditions, IL-17A expressing cells were reduced for KSR1-/- (3.20% ± 1.5%) and KSR1-/-Il10-/- 
(5.9% ± 0.48%) compared to WT (13.48% ± 1.34%) and Il10-/- (37.43% ± 8.3%) CD4+TCRβ+ T 
cells (Figure 5A-B).  In fact, the number of CD4+TCRβ+ T cells producing IFN-γ was increased in 
KSR1-/- (10.32% ± 3.0%) and KSR1-/-Il10-/- (6.8% ± 1.7%) when compared to WT (0.89% ± 0.4%) 
and Il10-/- (2.84% ± 0.7%) even under Th17 polarizing conditions (Fig. 4.7A-B).  We then 
determined if loss of KSR1 promoted T cell development along the Th1 axis in vitro.  Splenocytes 
were isolated as and cultured under Th1 polarizing conditions and analyzed as before.  We found 
that cell expressing IFN-γ under Th1 polarization was increased in KSR1-/- CD4+TCRβ+ T cells 
(56.1% ± 1.9%) compared to WT (44.8% ± 3.4%) (Fig. 4.8A-B).  Interestingly, culturing 
splenocytes from KSR1-/-Il10-/- mice under Th1 polarizing conditions resulted in reduced T cell 
viability.  These findings suggest that KSR1-/- T cells have a greater propensity to develop along 
the Th1 axis in vitro. 
 
IFN-γ production is increased in lymphocytes isolated from Rag2-/- mice previously transferred 
with KSR1-/- or KSR1-/-Il10-/- naïve T cells  
Adoptive transfer of CD4+CD45RBhigh naïve T cells into immunodeficient recombination 
activating gene-2 (Rag2-/-) mice causes colitis (Powrie, et al., 1993; Shinkai, et al., 1992). Since 
KSR1 deficient T cells had increased IFN-γ production, we hypothesized that adoptive transfer of 
KSR1 deficient CD4+CD45RBhigh naïve T cells into Rag2-/- mice would accelerate colitis.  To test 
this, we injected WT, KSR1-/-, or KSR1-/-Il10-/- CD4+CD45RBhigh naïve T cells into 8-week old 
Rag2-/- mice.  After 4 weeks, proximal and distal colon histological sections were scored for 
colitis.  Interestingly, the colitis that developed in Rag2-/- mice transferred with CD4+CD45RBhigh T 
cells was similar regardless of donor genotypes (Fig. 4.9).  Concurrently we isolated spleen,  
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Figure 4.9: KSR1 deficiency does not exacerbate colitis following adoptive transfer of 
CD4+CD45RBhigh T cells into Rag2-/- mice.   Mouse colons were removed and a 2 mm section 
cut from proximal and distal colon was fixed and paraffin embedded. H&E stained sections were 
scored by a pathologist blinded to the groups as previously described (Corazza, et al., 1999). 
Solid bars represent the mean colitis score for each group (n ≥ 6) and error bars are the SEM 
from two independent experiments. 
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mesenteric lymph node (MLN), and intraepithelial lymphocyte (IEL) donor T cells, stimulated with 
PMA/Ionomycin, and stained for intracellular IFN-γ and IL-17A and analyzed by flow cytometry.  
The percentage of IFN-γ producing CD4+TCRβ+ T cells isolated from spleens of Rag2-/- mice 
transferred with KSR1-/- and KSR1-/-Il10-/- naïve T cells was increased (39.4% ± 5.3% and 41.2% 
± 1.5% respectively) compared to transferred WT naïve cells (24. 6% ± 1.6%) (Figs. 4.10A, 
4.10C).  Additionally, donor KSR1-/- and KSR1-/-Il10-/- CD4+ T cells isolated from the spleen had 
fewer T cells expressing IL-17A (1.0% ± 0.1% and 0.6% ± 0.4%) compared to WT (2.5% ± 0.4%) 
(Figs. 4.10B-C).  Similar results were obtained for KSR1-/- and KSR1-/-Il10-/- T cells isolated from 
the MLN of Rag2-/- mice. Interestingly, IFN-γ in T cells isolated from IEL fractions was not 
increased and only KSR1-/-Il10-/- IEL exhibited a decrease in IL-17A production (Figs. 4.10B-C).  
These data suggest that the effect of KSR1 deficiency in colitis may require loss of KSR1 in 
innate immune cells to exacerbate disease, or that the increased IFN-γ production by CD4+TCRβ+ 
T cells is insufficient to increase colitis severity in the Rag2-/- transfer model. 
 
Neutralization of IFN-γ attenuates severity of disease in KSR1-/-Il10-/- mice 
Our data showing that colons of KSR1-/- and KSR1-/-Il10-/- mice had increased in IFN-γ 
mRNA levels, together with the data indicating KSR1-/- and KSR1-/-Il10-/- CD4+ T cells have 
enhanced IFN-γ production, suggest a potential mechanism for accelerated disease in KSR1-/-
Il10-/- mice.  Therefore, we determined if IFN-γ expression was involved in disease pathogenesis 
in KSR1-/-Il10-/- mice.  To test this, we administered intraperitoneal injections of α-IgG, α-IFN-γ, or 
α-IL-17A neutralizing antibodies in 3-week old KSR1-/-Il10-/- mice twice per week for 3 weeks.  
Three days following the last injection, mice were sacrificed and H&E stained colon sections were 
scored for inflammation and injury as before.  While neutralization of IL-17A caused no 
discernable decrease in colitis severity over isotype control (8.75 ± 1.5 vs. 9.75 ± 1.0), treatment 
with anti-IFN-γ significantly reduced the severity of colitis (6.3 ± 1.1) in KSR1-/-Il10-/- mice (Figs. 
4.11A-B).  As expected, α-IL-17A reduced KC expression indicating IL-17A inhibition (Fig. 4.11C).   
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Figure 4.10: KSR1-/- and KSR1-/-Il10-/- T lymphocytes re-isolated from Rag2-/- mice have 
increased IFN-γ  production and reduced IL-17A production.  Naïve CD4+CD45Rβhigh T 
lymphocytes sorted from WT, KSR1-/-, and KSR1-/-Il10-/- mouse spleens were injected into 8-week 
old Rag2-/- mice and followed for 4 weeks post-injection. T cells isolated from the spleen, MLN, or 
IEL populations were cultured for 5 hours in the presence of the protein transport inhibitor 
GolgiPlug and treated with or without PMA/Ionomycin.  Intracellular A) IFN-γ and B) IL-17A 
staining of CD4+TCRβ+ T cells were analyzed by flow cytometry.  C) Intracellular cytokine staining 
for IFN-γ and IL-17A was quantified for each isolated T cell population and the mean is 
represented by solid bars for each indicated group as well as the mean ratio of T cells positive for 
intracellular IFN-γ compared to T cells positive for intracellular IL-17A.  Error bars represent the 
SEM pooled from two independent experiments (n ≥ 4).  * P < 0.05, ** P < 0.01, *** P < 0.001 
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Figure 4.11: Neutralizing IFN-γ  attenuates colitis in KSR1-/-Il10-/- mice.  3-week old KSR1-/-
Il10-/- mice were administered intraperitoneal injections of 100 µg/mouse neutralizing antibodies 
against IgG, IFN-γ, or IL-17A twice per week for a period of 3 weeks and assessed for colitis.  A) 
Colon sections were scored as before for inflammation and injury.  Solid bars represent the mean 
(n = 5) pooled from three independent experiments with the error bars representing the SEM.  B) 
Representative H&E stained colon sections from KSR1-/-Il10-/- mice administered IgG, IFN-γ, or IL-
17A neutralizing antibody. C) Efficacy of IL-17A neutralizing antibody was examined by 
determining KC transcript levels using quantitative real-time PCR analysis on RNA isolated from 
colons of KSR1-/-Il10-/- mice administered IgG or IL-17A neutralizing antibody.  Solid bars are the 
mean (n=5) and error bars represent the SEM from three independent experiments.  * P < 0.05 
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These data indicate that the severity of colitis in KSR1-/-Il10-/- mice is mediated, at least in part, by 
the increase of IFN-γ associated with loss of KSR1. 
 
KSR1-/- mice have increased susceptibility to DSS-induced experimental colitis 
Oral administration of DSS results in colitis characterized by Th1 cytokines during the 
acute phase of disease (Dieleman, et al., 1998).   While lymphocytes are not required for DSS-
induced injury (Dieleman, et al., 1994), Th1 lymphocytes play detrimental roles in DSS-induced 
colitis (Kim, et al., 2006).   Since colitis in KSR1-/-Il10-/- mice is, in part, mediated by IFN-γ, 
combined with the observation that KSR1-/- CD4+TCRβ+ T cells have enhanced IFN-γ production, 
we hypothesized that KSR1 is protective against DSS-induced experimental colitis.  To assess 
the role of KSR1 in DSS-induced colitis, 8-week old WT and KSR1-/- mice were administered 3% 
DSS in the drinking water for a period of 7 days.  Some mice were allowed to recover following 
the DSS-induced injury by administering regular drinking water for 3 days following DSS 
treatment.  While the percent initial body weight was relatively unchanged in WT and KSR1-/- 
given water or DSS, KSR1-/- mice continued weight loss during the recovery period (88.8% ± 
1.6%) compared to WT mice (96.9% ± 1.2%) (Fig. 4.12A).  We then examined for histological 
changes using H&E staining paraffin embedded mouse colon sections (Fig. 4.12B) which were 
scored by a pathologist blinded to the genotype and treatment group.  While the injury scores for 
KSR1-/- mice following the 7-day DSS treatment were statistically indistinguishable from WT (7.4 ± 
1.1 vs. 9.1 ± 1.0), KSR1-/- mice had increased injury scores following the 3-day recovery period 
(13.3 ± 0.68) compared to WT (8.9 ± 0.71) (Fig. 4.12C).  Interestingly, while injury scores in 
KSR1-/- mice increased following the recovery phase compared to the 7-day injury, injury in WT 
mice was similar for both 7-day injury and 3-day recovery (Fig 4.12C).  Thus, KSR1 appears to be 
an important molecule that protects against Th1 experimental models of colitis. 
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Figure 4.12: KSR1-/- mice have increased sensitivity to DSS-induced colitis.  8-week old WT 
and KSR1-/- mice were administered 3% DSS (w/v) in the drinking water for a period of 7 days.  
Subsets of mice were provided regular drinking water for 3 days following DSS treatment. A) Mice 
were weighted daily and recorded as a percent of initial body weight.  Data are plotted as the 
mean percentage with error bars representing the SEM from two independent experiments (n = 
8).   * P < 0.05, ** P < 0.01  B) Paraffin embedded mouse colon sections were H&E stained.  
Images were taken at 10X magnification (scale bars, 20 µm).  C)  H&E stained colon sections 
were scored for inflammation and injury by a pathologist blinded to the genotype and treatment 
group.  Solid bars represent the mean injury and inflammation score for each group (n = 8) and 
error bars are the SEM from two independent experiments.  ** P < 0.01 
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Discussion 
While distinct roles for KSR1 have been reported for intestinal epithelial cells (Yan, et al., 
2001; Yan, et al., 2004), T cell proliferation (Nguyen, et al., 2002), T cell differentiation,(Wang, et 
al., 2004; Wang, et al., 2006) and recently NK cell-mediated cytolysis (Giurisato, et al., 2009), the 
role of KSR1 in inflammatory diseases has not been defined.  In this study, we utilized the Il10-/- 
mouse model of spontaneous experimental colitis to investigate the role of KSR1 during chronic 
inflammation.  We found that KSR1-/-Il10-/- mice developed accelerated severe colitis with 100% 
penetrance by 4 weeks of age.  The pathogenesis of the disease was predominantly attributed to 
loss of KSR1 in hematopoietic lineages.  We found that splenocytes isolated from KSR1-/- and 
KSR1-/-Il10-/- mice exhibited increased IFN-γ production.  In fact, KSR1 deficient splenocytes had 
a greater propensity to develop along the Th1 axis while Th17 development was impaired in vitro.  
Finally, administration of α-IFN-γ neutralizing antibody attenuated colitis in KSR1-/-Il10-/- mice.  
Collectively, the data presented here implicate KSR1 as a regulatory molecule that functions to 
suppress IFN-γ production in T cells and promotes Th1/Th17 developmental homeostasis. 
Spontaneous colitis in Il10-/- mice requires interaction with luminal bacteria (Kühn, et al., 
1993; Sellon, et al., 1998).  Since KSR1-/-Il10-/- mice develop colitis by 4 weeks of age, and that 
enteric microbial populations are established just post-weaning (Savage, et al., 1968), we initially 
suspected that KSR1 was involved in epithelial barrier integrity.  Though epithelial barrier 
permeability was detected in 10-week old KSR1-/-Il10-/- mice, KSR1-/- and Il10-/- mice were similar 
to that of WT mice at 10 weeks of age (Fig. 4.2A).  Although KSR1 protects from TNF-induced 
apoptosis in colon epithelial cells (Yan, et al., 2001; Yan, et al., 2004), it does not appear to be 
required for barrier function in the absence of challenging conditions. 
We were surprised to find that the protective role of KSR1 was mostly attributed to cells 
of the immune system (Fig. 4.3).  Previous data indicate that Il10-/- BM is insufficient to cause 
disease in WT mice, consistent with our findings (Bamba, et al., 2006).  The fact that KSR1-/-Il10-/- 
BM was sufficient to cause disease in WT recipients established a clear role for KSR1 in immune 
cell function.  Since IFN-γ and IL-17A transcripts were elevated in the colon of healthy KSR1-/- 
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mice and diseased KSR1-/-Il10-/- mice (Fig. 4.5), it seemed plausible that KSR1 was involved in T 
cell development or in Th1/Th17 responses.  Though current data on the pathogenesis of IL-17 in 
inflammatory diseases remains unclear (Fujino, et al., 2003; Haak, et al., 2009; Komiyama, et al., 
2006; Nakae, et al., 2003), our data revealed that colitis in KSR1-/-Il10-/- mice was attenuated by 
inhibiting IFN-γ and not IL-17A (Fig. 4.11).  In a second colitis model involving Th1-mediated 
pathogenesis (Kim, et al., 2006), KSR1-/- mice also exhibited greater sensitivity to DSS-induced 
injury compared to WT mice (Fig. 4.12), further implicating KSR1 in pathogenic Th1 responses.  
 The observation that in vitro Th1 polarization was enhanced in KSR1-/- CD4+TCRβ+ cells 
(Fig. 4.8) while Th17 polarization was impaired (Fig. 4.7), suggest KSR1 is involved in Th1 
development and suppresses IFN-γ production.  While the exact mechanism by which KSR1 
suppresses T cell IFN-γ expression is presently not yet understood, scaffolding proteins including 
KSR1 can modulate signaling pathways by localization of protein phosphatases.  KSR1 interacts 
with protein phosphatase 2B (PP2B) to uncouple ERK activation from the transcriptional activity 
of Elk-1 (Sugimoto, et al., 1998) as well as associates with PP2A (Ory, et al., 2003).  It is 
attractive to speculate that an antigenic stimulus in the absence of KSR1 perturbs signaling 
pathways normally regulated by phosphatases.  For instance, suppression of PP2A activity 
increases IFN-γ production in NK cells in the innate immune system (Trotta, et al., 2007).  Future 
analysis on KSR1-interacting proteins in T lymphocytes will be important to identify genes 
involved in this response.    
The crosstalk between innate immune defenses and acquired immunity is actively being 
investigated for autoimmune diseases and IBD (Kalyan, et al., 2009; Pletneva, et al., 2009; 
Stockinger, et al., 2007).  While our data support a role for KSR1 in lymphocyte function, we 
cannot rule out a role for KSR1 in innate immunity.  The observation that Rag2-/- mice transferred 
with CD4+CD45RBhigh naïve T cells from WT, KSR1-/-, or KSR1-/-Il10-/- developed comparable 
disease with similar histological colitis scores (Fig. 4.9) was surprising given that isolated donor 
KSR1-/- and KSR1-/-Il10-/- naïve T cells produced more IFN-γ (Fig. 4.10A).  One possibility is that 
WT colitogenic T cells express appreciable levels of IFN-γ and further increases due to KSR1 
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deficiency may be insufficient to exacerbate the disease.  Alternatively, KSR1 deficiency in the 
innate immune system may be an important component for increasing susceptibility to colitis 
mice.  Since Rag2-/- mice possess KSR1 in cells of the innate immune system independent of 
transferred T cell genotype, colitis would develop independent of the genotype of transferred 
CD4+CD45RBhigh naïve T cells.  Consistent with a functional role for KSR1 in innate immune 
system, we observed decreased nitric oxide production from stimulated bone marrow derived 
KSR1-/- macrophages (unpublished observations).  While emerging data implicate KSR1 in innate 
immune cell function (Giurisato, et al., 2009), further investigations are necessary to elucidate 
what role, if any, KSR1 plays in innate immune responses and the susceptibility to colitis.  
Finally, there may be a direct connection between vitamin D and KSR1 in immunity.  
Vitamin D receptor (VDR) signaling regulates T cell development and helps maintain 
immunological tolerance with implications for multiple sclerosis, type-1 diabetes mellitus, and IBD 
(Cantorna, 2006; Ginanjar, et al., 2007).  Recently, polymorphisms at the VDR locus were linked 
to IBD and other autoimmune disorders (Naderi, et al., 2008).  Vitamin D supplementation holds 
promise as a therapeutic agent in the treatment of Crohnʼs disease by increasing NOD2 
expression, which then couples to the expression the antimicrobial peptide defensin β2 (Wang, et 
al., 2010).  Interestingly, the KSR1 promoter contains a vitamin D responsive element and 
moreover, KSR1 protein is upregulated by 1, α25-dihydroxyvitamin D3 (Wang, et al., 2006).  In 
fact, VDR-/-Il10-/- mice develop severe accelerated spontaneous colitis harboring many phenotypic 
similarities to those observed in KSR1-/-Il10-/- mice including increased levels of IFN-γ (Froicu, et 
al., 2003; Froicu, et al., 2006).  It is attractive to speculate that vitamin D-mediated suppression of 
pathogenic immune responses is, in part, regulated by KSR1 expression and suppression of IFN-
γ production in Th1 effector cells.   
We conclude that KSR1 expression suppresses IFN-γ production in T lymphocytes by 
promoting T cell homeostasis along the Th1/Th17 axis.  Therefore, induction of KSR1 expression 
may be an ideal strategy for modulating IFN-γ in Th1-mediated diseases. 
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CHAPTER V 
 
SUMMARY AND FUTURE DIRECTIONS 
 
Summary of findings 
The results of the work comprised in this dissertation contribute to our understanding of 
KSR1 as a functional protein kinase in the ERK pathway and describe a new role for KSR1 in 
immune regulation in vivo.  While the kinase activity of KSR1 has remained contentious over the 
past 15 years, the data in Chapter III demonstrate that the kinase activity of KSR1, together with 
MEK kinase activity, promote colon epithelial cell survival in response to TNF.  We show that 
recombinant KSR1 expressed and recovered from bacteria possesses intrinsic kinase activity and 
autophosphorylates on serine independent of ceramide.  In addition, recombinant KSR1 
phosphorylates MBP as a generic substrate and directly phosphorylates recombinant MEK.  The 
kinase activity of KSR1 required full length KSR1 protein since an N-terminal deletion 
(KSR1ΔCA1) and expression of the kinase domain alone (KSR1ΔN521) had no detectable 
catalytic activity.  Interestingly, while recombinant KSR1 is insufficient to promote MEK activation, 
phosphorylation of recombinant MEK by immunoprecipitated KSR1 is able to promote MEK 
activity towards recombinant ERK.  
In Chapter IV we described a new role for KSR1 in protection from a Th1-mediated 
mouse model of colitis.  Though KSR1-/- mice were phenotypically normal, loss of KSR1 in the 
Il10-/- mouse model of spontaneous colitis resulted in accelerated severe colitis that was 
characterized by increased epithelial cell turnover and elevated mucosal IFN-γ and IL-17A.  We 
show that KSR1 deficiency in CD4+ T lymphocytes resulted in enhanced IFN-γ production.   This 
is attributed to a greater propensity of KSR1-/- naïve T cells to develop along the Th1 lineage in 
vitro.  Not only was Th1 polarization enhanced in KSR1 deficient T cells; in vitro Th17 polarization 
was impaired.   Furthermore, neutralization of IFN-γ attenuated colitis in KSR1-/-Il10-/- mice.  
Consistent with a role in protecting against Th1-mediated colitis, KSR1-/- mice exhibited greater 
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sensitivity to the DSS-induced injury model of colitis.  While elevated IFN-γ increased severity of 
colitis in KSR1-/-Il10-/- mice, IFN-γ expressing T cells did not cause increased colitis in an adoptive 
transfer model using lymphocyte deficient Rag2-/- mice.  This suggests that, in addition to a role in 
the adaptive immune system, KSR1 may also function in the innate immune system to suppress 
colitis.  We conclude that KSR1 expression protects from Th1-mediated colitis by suppressing 
IFN-γ production and promotes T cell developmental homeostasis along the Th1/Th17 axis. 
 
Future directions 
 
KSR1 as a functional protein kinase 
Our data detailed in Chapter III indicate that KSR1 is a functional protein kinase involved 
in the colon epithelial cell survival response downstream of TNF signaling.  While we 
demonstrated that recombinant KSR1 autophosphorylates on serine, we have yet to identify the 
specific autophosphorylation site.  Using 2D tryptic phosphopeptide mapping we found that KSR1 
autophosphorylation occurs on a single tryptic peptide suggesting a single or limited number of 
autophosphorylation sites.  Since many protein kinases are activated by phosphorylation within or 
near the kinase domain, it will be important to identify this site and determine if KSR1 
autophosphorylation is a prerequisite for KSR1 kinase activity towards MEK and for TNF-
mediated cell survival.  KSR1 contain two serines in the kinase domain activation loop, Ser707 
and Ser722, which are good candidates for future analysis.  KSR1 also contains a serine 
bracketed by an F-S-L-F motif C-terminal to the kinase domain.  This is highly similar to the C-
terminal hydrophobic F-x-x-F/Y-S/T-Y/F motif found in many AGC protein kinases such as protein 
kinase B (PKB).  For PKB, protein stability, kinase activity, and PDK1 binding in the kinase 
domain are increased when the serine following the FxxF motif is phosphorylated (Romano, et al., 
2009).  It will be interesting to see if KSR1 is autophosphorylated at this serine residue and what 
effect a phosphomimetic mutant would have on KSR1 stability, MEK association, and protein 
kinase activity.  In addition, MEK activation requires phosphorylation at two serines in the MEK 
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activation loop.  We observed MEK activation in vitro using KSR1 immunoprecipitated from 
mammalian cells but not recombinant KSR1.  This could be expected if KSR1 in mammalian cells 
has higher catalytic activity due to post-translational modifications.  KSR1 is phosphorylated at a 
number of sites outside the kinase domain by other protein kinases (Volle, et al., 1999).  
Therefore, site-directed mutagenesis at known KSR1 phosphorylation sites would determine if 
any modulate KSR1 kinase activity.  Alternatively, if KSR1 preferentially phosphorylates one MEK 
serine residue over the other, it would suggest a mechanism by which KSR1 could sensitize the 
pathway by reducing the threshold for Raf-1-medaited ERK activation.  However, if KSR1 
phosphorylates both sites equivalently, KSR1 might sustain MEK activation following Raf-1 
dissociation (Figure 5.1A-B).   Lastly, the observation that KSR1 kinase activity required full-
length KSR1 protein may offer clues into the tertiary structure of KSR1.  For many kinases, 
expression of the kinase domain alone results in a constitutively active enzyme.  Since the KSR1 
kinase domain alone or a deletion of the CA1 domain resulted in a non-functional kinase, studies 
should be conducted to determine if the CA1 and kinase domain of KSR1 interact and what 
impact this interaction has on catalytic activity.  
 
Role of KSR1 in colitis 
 In Chapter IV we describe the physiological characteristics that exacerbate colitis in 
KSR1-/-Il10-/- mice.  Specifically, increased IFN-γ in KSR1-/-Il10-/- mice resulted in a severe early 
onset colitis that could be attenuated by blocking IFN-γ in vivo.  In mouse models of autoimmune 
disorders such as Rheumatoid arthritis and multiple sclerosis, blocking IFN-γ is an effective 
therapeutic strategy (Skurkovich, et al., 2007).  We demonstrated that CD4+ T cells lacking KSR1 
had a greater propensity to develop along the Th1 axis and produced more IFN-γ upon 
stimulation compared to WT CD4+ T cells.  Yet, the mechanism by which KSR1 suppresses IFN-γ 
production remains unknown.  Since IFN-γ functions in a positive feedback loop, KSR1 could 
regulate induction of IFN-γ by IL-12 (Figure 5.2).  Work from others offer insight into how KSR1 
might play a role in this process as vitamin D suppresses IFN-γ synthesis  (Cippitelli, et al., 1998). 
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Figure 5.1:  Models of KSR1 kinase activity in MEK activation A) KSR1 N- and C-terminus 
interact to stabilize an active state of the KSR1 kinase domain.  KSR1-assocaited MEK is 
phosphorylated by KSR1 constitutively to lower the threshold of Raf-1-mediated activation of MEK 
in response to stimulus.  B)  KSR1 kinase activity is inhibited by sequestration of the N- and C-
terminus by an inhibitory protein such as 14-3-3.  Upon stimulation, inhibition by 14-3-3 is relieved 
allowing for the intramolecular interaction of the KSR1 CA1 and kinase domains.  This interaction 
promotes KSR1 kinase activity that function to maintain MEK activation following the dissociation 
of Raf-1. 
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Figure 5.2:  Model of KSR1 regulation of T cell IFN-γ  production and Th1 development 
Differentiation of naïve CD4+ T lymphocytes into Th1 subtypes requires ligation of TCR in the 
presence of IL-12.  IL-12 signals through IL-12R to drive IFN-γ production and positively regulates 
Th1 development.  TCR signals through PLCγ1 to activate the Ras-MAPK cascade and promote 
transcription of Th2 related genes.  Adapted from {Liew, 2002 #422} and {Yamashita, 2005 #423} 
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Work from Studzinskiʼs group demonstrated that KSR1 expression is under the control of a 
vitamin D responsive element (Wang, et al., 2006).  They also found that KSR1 expression 
modulates monocyte differentiation induced by vitamin D (Wang, et al., 2004).  In fact, vitamin D 
receptor (VDR) knockout mice crossed with Il10-/- mice develop similar disease characteristics as 
KSR1-/-Il10-/- mice (Froicu, et al., 2006).  Perhaps VDR-/-Il10-/- mice develop disease due to 
reduced KSR1 protein levels.  While it appears these two components intersect in IL-10 
deficiency-induced colitis, further work is needed to determine how KSR1 functions in 
suppression of IFN-γ production in T cells.  Nevertheless, data from our adaptive transfer 
experiments into Rag2-/- mice indicate that, in addition to the adaptive immune response, KSR1 
may also function in innate immunity to suppress disease.  Recent data demonstrate that KSR1 is 
required for proper NK cell-mediated lysis (Giurisato, et al., 2009), and preliminary data from our 
lab found that bone marrow-derived macrophage from KSR1-/- mice are impaired in H. pylori-
stimulated nitric oxide production.  Performing the adoptive transfer experiments on KSR1-/-Rag2-
/- mice would determine the requirement for KSR1 in the innate immune system to protect against 
colitis.  In addition, characterization of KSR1 function in macrophage is needed to assess KSR1 
involvement in macrophage activation by other stimulus such as LPS.  Defect in macrophage 
ability to clear invading pathogens may also contribute to the exacerbated disease in KSR1-/-Il10-/- 
mice.  Nevertheless, our data in Chapter III indicates that KSR1 promotes epithelial cell survival in 
colon epithelial cells.  Since our in vivo inflammation studies utilized a KSR1 deficient mouse that 
was generated as a global deletion, generation of a mouse containing floxed alleles at the KSR1 
locus will need to be crossed with the transgenic mouse expressing Cre recombinase under the 
control of an epithelial-specific villin promoter to investigate tissue-specific contributions of KSR1 
in colitis.  
 Ever since Rudolf Virchow made a correlation between inflammation and tumorigenesis 
nearly 150 years ago, the consequences emanating from chronic inflammation have been 
appreciated.  The effects of chronic inflammation on colonic tumor progression are mediated in 
part  through  epithelial  cell  survival   (Greten, et al., 2004).    Since our  data  show  KSR1  to be  
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Figure 5.3:  AOM-DSS treatment promotes adenomas in WT mice and flat adenomas with 
regenerative alterations in KSR1-/- mice  WT and KSR1-/- mice were given a single injection of 
PBS or AOM.  7 days later, a subset of these mice were administered DSS in the drinking water 
for 5 days followed by a 16-day recovery period on normal drinking water.  The cycle was 
repeated 2 more times and mice were sacrificed at the end of the last recovery period.  A) 
Colonoscopy images taken from AOM-DSS treated WT mice (top) and KSR1-/- mice (bottom) 
following the final cycle.  B) Image of whole colons isolated from WT mice (left) or KSR1-/- mice 
(right) treated with AOM-DSS.  C) Macroscopic images of the distal colon architecture from AOM-
DSS treated WT mice (top) and KSR1-/- mice (bottom).  D) Total injury scores for WT mice and 
KSR1-/- mice treated with water, AOM, PBS-DSS, or AOM-DSS.  Solid bars are the mean and the 
error bars are the SEM from two independent experiments (n ≥ 8). *** P  < 0.001 
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involved in TNF-mediated epithelial cell survival and pro-inflammatory Th1 responses, we 
investigated the role of KSR1 in colitis-associated cancer using the mutagen azoxymethane 
(AOM) followed by three rounds of DSS treatment.  Our preliminary data show that WT mice 
administered AOM-DSS develop classic adenoma polyps whereas KSR1-/- mice had no 
distinguishable polyps, but instead displayed large ulcerations with regenerative crypt changes 
(Figure 5.3).  These characteristics are similar to those seen for mice expressing oncogenic K-
Ras in the colonic epithelium in combination with a second tumor-promoting mutation in APC 
(Haigis, et al., 2008).  These mutations contribute to the grade and metastatic potential of tumor 
progression that is partially attributed to a reduction in ERK activation (Haigis, et al., 2008).  
Further analysis comparing the mutations arising in AOM-DSS treated WT mice vs. AOM-DSS 
treated KSR1-/- mice by Laser capture microdissection will determine if there is a disparity in the 
occurrence of particular oncogenic mutations between the two distinct types of tumor growth.  In 
addition, for the oncogenic K-Ras mouse model, the MAP kinase phosphatase 3 (Mkp3) was 
upregulated and functioned to reduce ERK signaling.  Mkp3 expression in AOM-DSS treated 
KSR1-/- mice should be examined to determine if loss of KSR1 contributes to regenerative 
changes due to Mpk3 gene expression.  Alternatively, enhanced inflammatory responses and 
slow restitution in response to DSS-induced injury might increase the instance of inflammation-
associated mutagenesis.   
 
Concluding remarks 
 Initial observations nearly 30 years ago began to unravel a basic sequential signal 
transduction mechanism utilized by all eukaryotes known as the MAPK cascade (Cobb, et al., 
1983).  The ERK/MAPK pathway is one of several MAPK signaling modules that utilizes a tiered 
signaling cascade to instruct a diverse range of cellular functions from yeast to mammals.  Since 
this pathway is activated downstream from a variety of extracellular signals, specific responses 
are often determined by regulation over signal duration and/or activation threshold.  Scaffolding 
proteins such as Ste5 in yeast, or KSR1 and MEKK1 in mammals, facilitate activation of the 
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MAPK cascade by association with each MAPK cascade component.  However, recent evidence 
points to more complex mechanisms by which scaffolding proteins fine-tune pathway activation to 
coordinate diverse signaling output.  An elegant set of experiments demonstrated that 
dimerization of Raf and KSR1 enhances Raf activation through an allosteric mechanism 
(Rajakulendran, et al., 2009).  A similar mechanism was described for Fus3 activation by the 
yeast scaffolding protein Ste5 (Bhattacharyya, et al., 2006).  Furthermore, the diverse system 
output in response to ERK activation suggests that the pathway itself is highly plastic.   This can 
partly be attributed to the fact that activation of the ERK pathway can occur as a graded or digital 
response based on the type of stimulus.  The response to stimulus can also be changed by the 
sensitivity to a given ligand-induced signal.  In many ways KSR1 functions like a variable rheostat 
that enhances the sensitivity to a particular stimulus by altering the ERK activation threshold (Lin, 
et al., 2009).  However, the exact mechanism by which KSR1 functions to achieve this 
sensitization is not entirely clear.  Based on our in vitro data using recombinant KSR1 protein, we 
propose two models in which KSR1 kinase activity contributes to MEK activation.  In the first 
model the KSR1 N-terminus directly interacts with the C-terminal kinase domain to allosterically 
modulate KSR1 kinase activity towards MEK and lower the threshold for MEK activation by Raf-1 
(Figure 5.1A).  Alternatively, inhibitory proteins such as 14-3-3 proteins may sequester the N- and 
C-terminus of KSR1 to suppress KSR1 activity.  Ligation of TNF promotes dissociation of 14-3-3 
proteins, allowing an intramolecular interaction to occur between the KSR1 CA1 domain and the 
KSR1 kinase domain.  Dissociation of 14-3-3 from KSR1 also allows for KSR1 association with 
Raf-1, which leads to Raf-1 activation of MEK.  Following Raf-1 dissociation from KSR1, KSR1 
could function to sustain MEK activation in the absence of Raf-1 spatially within the cell to 
maintain ERK activation (Figure 5.1B).  
In many human cancers, activation of the ERK pathway due to constitutive signaling from 
oncogenic mutations in RTK and Ras are common occurrences (Kranenburg, 2005; Meshinchi, et 
al., 2003).  While these cell-autonomous mutations are necessary for tumorigenesis, often times 
they are not sufficient.  One key factor that elevates risk for carcinogenesis is inflammation.  
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Under normal function the immunosurveillance can recognize and remove transformed cells 
(Smyth, et al., 2006).  However, free radicals generated by immune cells can result in oxidative 
damage to genomic DNA, promoting tumorigenesis.  Evidence for the tumor-promoting 
consequence of inflammation comes from patients with familial adenomatous polyposis (FAP).  
These individuals develop colonic tumors due to inherited mutations in the adenomatous 
polyposis coli (APC) gene.  Fewer polyps are observed when these patients are treated with non-
steroidal anti-inflammatory drugs (NSAIDs)	   (Ulrich, et al., 2006).  In a similar manner, patients 
with IBD have a greater risk for developing colon cancer with higher mortality rates than that for 
sporadic colon cancer due to repeated bouts of inflammation (Ekbom, et al., 1990; Richards, et 
al., 1989).  Animal models have provided clues into the potential mechanisms driving 
inflammation-associated cancer.  One key factor found to mediate the tumor promoting effects of 
inflammation in the colon is the anti-apoptotic transcription actor NF-κB expressed in colon 
epithelial cells (Greten, et al., 2004).  TNF, predominantly produced by monocytes, activates NF-
κB downstream of TNFR1	  (Edelblum, et al., 2008).  By promoting colon epithelial cell survival in 
the presence of DNA damaging byproducts from immune cells, epithelial cells acquire mutations 
that circumvent an apoptotic program and instead, pass along oncogenic mutations to progenitor 
cells.  Since KSR1 promotes TNF-mediated colon epithelial cell survival, as detailed in Chapter 
III, KSR1 expression may actually be tumor promoting in the context of inflammation.  Targeting 
KSR1 expression in early stages of tumor development may reduce the overall tumor burden and 
progression towards metastasis.  In fact, loss of KSR1 expression disrupts oncogenic Ras 
signaling and prevents pancreatic carcinoma xenografts in nude mice (Xing, et al., 2003).   
For patients with chronic inflammation, dysregulated immune responses not only 
increase discomfort and impact quality of life; the risk of developing inflammation-associated 
cancer is increased.  With the data presented in Chapter IV, promoting KSR1 expression in the 
immune system may be a viable strategy to reduce IFN-γ gene transcription and promote T cell 
developmental homeostasis and decrease inflammation-associated cancer risk.  These data 
position KSR1 an attractive molecule to suppress IFN-γ production in Th1 lymphocytes, as well as 
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to disrupt cell survival cues in Ras-dependent tumors.  Thus, modulating KSR1 protein 
expression in a tissue specific manner may be a viable strategy to attenuate Th1 inflammatory 
responses and decrease cancer risk associated with chronic inflammation. 	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